Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	TCP10L NCOA2 BCL9L NCOA3 NCOR2 KMT2C SYNPO2 NDC1 BAZ2A SS18L1 MARK4 TNRC6A MAML1 AKAP13 MED13L TRRAP SS18 ANAPC7 CREBBP MAML3 CNOT2	1.43e-08	1160	86	21	GO:0030674
GeneOntologyMolecularFunction	molecular adaptor activity	TCP10L NCOA2 BCL9L NCOA3 NCOR2 KMT2C SYNPO2 NDC1 BAZ2A SS18L1 MARK4 TNRC6A MAML1 AKAP13 MED13L TRRAP SS18 ANAPC7 CREBBP MAML3 CNOT2 SEPTIN2	4.28e-08	1356	86	22	GO:0060090
GeneOntologyMolecularFunction	transcription coregulator activity	TCP10L NCOA2 BCL9L NCOA3 NCOR2 KMT2C SS18L1 MAML1 MED13L TRRAP SS18 CREBBP MAML3 CNOT2	1.17e-07	562	86	14	GO:0003712
GeneOntologyMolecularFunction	transcription coactivator activity	NCOA2 BCL9L NCOA3 KMT2C SS18L1 MAML1 TRRAP SS18 CREBBP MAML3	7.14e-07	303	86	10	GO:0003713
GeneOntologyMolecularFunction	nuclear receptor binding	NCOA2 NCOA3 NCOR2 BAZ2A NR4A2 TACC2 PPID	1.63e-05	187	86	7	GO:0016922
GeneOntologyMolecularFunction	nuclear glucocorticoid receptor binding	NCOA2 NCOR2 NR4A2	8.34e-05	20	86	3	GO:0035259
GeneOntologyMolecularFunction	transcription factor binding	TCP10L NCOA2 NCOA3 NCOR2 BAZ2A NR4A2 TACC2 MAP3K7 PPID CREBBP CNOT2 PYHIN1	8.96e-05	753	86	12	GO:0008134
GeneOntologyMolecularFunction	protein domain specific binding	SHISA9 NCOA2 NCOA3 HIVEP1 TP63 TOM1L1 CXXC4 TNK2 CARD11 TACC2 SHROOM2 CREBBP TRAK1	9.03e-05	875	86	13	GO:0019904
GeneOntologyMolecularFunction	nuclear retinoid X receptor binding	NCOA2 NCOR2 NR4A2	1.28e-04	23	86	3	GO:0046965
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	TCP10L NCOA2 NCOA3 NCOR2 BAZ2A NR4A2 TACC2 MAP3K7 PPID CREBBP	1.98e-04	582	86	10	GO:0140297
GeneOntologyMolecularFunction	RNA polymerase II-specific DNA-binding transcription factor binding	NCOA2 NCOA3 NCOR2 BAZ2A NR4A2 TACC2 PPID CREBBP	4.33e-04	417	86	8	GO:0061629
GeneOntologyMolecularFunction	ubiquitin binding	TOM1L1 MARK4 N4BP1 MAP3K7	1.18e-03	107	86	4	GO:0043130
GeneOntologyMolecularFunction	RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding	NCOA2 HIVEP1	1.39e-03	13	86	2	GO:0001162
GeneOntologyMolecularFunction	nuclear estrogen receptor binding	NCOA2 NCOA3 PPID	1.55e-03	53	86	3	GO:0030331
GeneOntologyMolecularFunction	nuclear retinoic acid receptor binding	NCOA2 NCOR2 NR4A2	1.72e-03	55	86	3	GO:0042974
GeneOntologyMolecularFunction	ubiquitin-like protein binding	TOM1L1 MARK4 N4BP1 MAP3K7	2.28e-03	128	86	4	GO:0032182
GeneOntologyMolecularFunction	nuclear receptor coactivator activity	NCOA2 NCOA3 SS18	2.32e-03	61	86	3	GO:0030374
GeneOntologyMolecularFunction	intronic transcription regulatory region sequence-specific DNA binding	NCOA2 HIVEP1	2.39e-03	17	86	2	GO:0001161
GeneOntologyBiologicalProcess	regulation of intracellular steroid hormone receptor signaling pathway	NCOA2 NCOA3 NCOR2 TP63 CNOT2	2.99e-05	87	85	5	GO:0033143
GeneOntologyBiologicalProcess	steroid hormone receptor signaling pathway	NCOA2 NCOA3 NCOR2 TP63 AKAP13 CNOT2	4.38e-05	155	85	6	GO:0043401
GeneOntologyBiologicalProcess	intracellular receptor signaling pathway	NCOA2 NCOA3 NCOR2 TP63 MARK4 NR4A2 XIAP MAP3K7 CNOT2	5.39e-05	416	85	9	GO:0030522
GeneOntologyBiologicalProcess	chromatin organization	TET2 NCOA3 KMT2C BRD2 BAZ2A TP63 SS18L1 EYA3 MAP3K7 TRRAP SS18 CREBBP HP1BP3	7.32e-05	896	85	13	GO:0006325
GeneOntologyCellularComponent	nuclear body	NCOA2 NCOR2 HIVEP1 BRD2 BAZ2A SS18L1 NR4A2 GPATCH2 MAML1 NCAM2 N4BP1 CREBBP MAML3 HP1BP3 PYHIN1	4.35e-06	903	87	15	GO:0016604
GeneOntologyCellularComponent	chromatin	NCOA2 NCOA3 NCOR2 KLF12 ZEB1 BRD2 BAZ2A TP63 SS18L1 NR4A2 MAP3K7 TRRAP SS18 ANAPC7 CREBBP HP1BP3	3.60e-04	1480	87	16	GO:0000785
GeneOntologyCellularComponent	nuclear speck	BRD2 BAZ2A NR4A2 GPATCH2 MAML1 MAML3 HP1BP3 PYHIN1	4.31e-04	431	87	8	GO:0016607
GeneOntologyCellularComponent	cortical actin cytoskeleton	SHROOM4 AKAP13 SHROOM2 SEPTIN2	6.16e-04	93	87	4	GO:0030864
GeneOntologyCellularComponent	SWI/SNF superfamily-type complex	BAZ2A SS18L1 TRRAP SS18	6.95e-04	96	87	4	GO:0070603
MousePheno	increased adiponectin level	NCOR2 ZEB1 BRD2 MARK3 CREBBP	4.06e-07	30	72	5	MP:0004892
MousePheno	abnormal adiponectin level	NCOA3 NCOR2 ZEB1 BRD2 MARK3 CREBBP	9.81e-07	65	72	6	MP:0004891
MousePheno	increased circulating adiponectin level	ZEB1 BRD2 MARK3 CREBBP	2.36e-06	19	72	4	MP:0030969
MousePheno	abnormal circulating adiponectin level	ZEB1 BRD2 MARK3 CREBBP	6.86e-05	43	72	4	MP:0030967
Domain	Nuc_rcpt_coact	NCOA2 NCOA3 CREBBP	1.87e-06	6	86	3	IPR009110
Domain	DUF4927	NCOA2 NCOA3	2.10e-05	2	86	2	PF16279
Domain	DUF4927	NCOA2 NCOA3	2.10e-05	2	86	2	IPR032565
Domain	Neuroggenic_mastermind-like_N	MAML1 MAML3	6.27e-05	3	86	2	IPR019082
Domain	DUF1518	NCOA2 NCOA3	6.27e-05	3	86	2	PF07469
Domain	DUF1518	NCOA2 NCOA3	6.27e-05	3	86	2	IPR010011
Domain	SSXT	SS18L1 SS18	6.27e-05	3	86	2	PF05030
Domain	Nuc_rcpt_coact_Ncoa-typ	NCOA2 NCOA3	6.27e-05	3	86	2	IPR014920
Domain	SRC-1	NCOA2 NCOA3	6.27e-05	3	86	2	IPR014935
Domain	MamL-1	MAML1 MAML3	6.27e-05	3	86	2	PF09596
Domain	Src1_rcpt_coact	NCOA2 NCOA3	6.27e-05	3	86	2	IPR008955
Domain	Nuclear_rcpt_coactivator	NCOA2 NCOA3	6.27e-05	3	86	2	IPR017426
Domain	DUF1518	NCOA2 NCOA3	6.27e-05	3	86	2	SM01151
Domain	MamL-1	MAML1 MAML3	6.27e-05	3	86	2	SM01275
Domain	SS18_fam	SS18L1 SS18	6.27e-05	3	86	2	IPR007726
Domain	SRC-1	NCOA2 NCOA3	6.27e-05	3	86	2	PF08832
Domain	-	NCOA2 NCOA3	6.27e-05	3	86	2	4.10.630.10
Domain	Nuc_rec_co-act	NCOA2 NCOA3	6.27e-05	3	86	2	PF08815
Domain	ASD2	SHROOM4 SHROOM2	1.25e-04	4	86	2	PF08687
Domain	MARK/par1	MARK3 MARK4	1.25e-04	4	86	2	IPR033624
Domain	ASD2	SHROOM4 SHROOM2	1.25e-04	4	86	2	PS51307
Domain	Shroom_fam	SHROOM4 SHROOM2	1.25e-04	4	86	2	IPR027685
Domain	ASD2_dom	SHROOM4 SHROOM2	1.25e-04	4	86	2	IPR014799
Domain	PAS	NCOA2 NCOA3 KCNH5	2.01e-04	25	86	3	PF00989
Domain	PAS_fold	NCOA2 NCOA3 KCNH5	2.01e-04	25	86	3	IPR013767
Domain	KA1_dom	MARK3 MARK4	2.08e-04	5	86	2	IPR001772
Domain	KA1	MARK3 MARK4	2.08e-04	5	86	2	PF02149
Domain	KA1	MARK3 MARK4	2.08e-04	5	86	2	PS50032
Domain	-	MARK3 MARK4	2.08e-04	5	86	2	3.30.310.80
Domain	Bromodomain_CS	BRD2 BAZ2A CREBBP	2.27e-04	26	86	3	IPR018359
Domain	AT_hook	KMT2C BAZ2A FAM171B	2.55e-04	27	86	3	SM00384
Domain	AT_hook_DNA-bd_motif	KMT2C BAZ2A FAM171B	2.55e-04	27	86	3	IPR017956
Domain	PAS	NCOA2 NCOA3 KCNH5	4.25e-04	32	86	3	SM00091
Domain	KA1/Ssp2_C	MARK3 MARK4	4.34e-04	7	86	2	IPR028375
Domain	PAS	NCOA2 NCOA3 KCNH5	5.09e-04	34	86	3	IPR000014
Domain	PAS	NCOA2 NCOA3 KCNH5	5.09e-04	34	86	3	PS50112
Domain	BROMODOMAIN_1	BRD2 BAZ2A CREBBP	6.54e-04	37	86	3	PS00633
Domain	Bromodomain	BRD2 BAZ2A CREBBP	7.08e-04	38	86	3	PF00439
Domain	BROMODOMAIN_2	BRD2 BAZ2A CREBBP	8.85e-04	41	86	3	PS50014
Domain	BROMO	BRD2 BAZ2A CREBBP	9.50e-04	42	86	3	SM00297
Domain	Bromodomain	BRD2 BAZ2A CREBBP	9.50e-04	42	86	3	IPR001487
Domain	-	BRD2 BAZ2A CREBBP	9.50e-04	42	86	3	1.20.920.10
Domain	AT_hook	KMT2C BAZ2A	2.41e-03	16	86	2	PF02178
Domain	-	KLC2 TANC1 TRRAP PPID ANAPC7	2.68e-03	207	86	5	1.25.40.10
Domain	TPR	KLC2 TANC1 PPID ANAPC7	2.98e-03	129	86	4	SM00028
Domain	TPR_repeat	KLC2 TANC1 PPID ANAPC7	3.33e-03	133	86	4	IPR019734
Domain	TPR-like_helical_dom	KLC2 TANC1 TRRAP PPID ANAPC7	4.44e-03	233	86	5	IPR011990
Domain	PDZ	SHROOM4 SYNPO2 CARD11 SHROOM2	4.86e-03	148	86	4	SM00228
Domain	PHD	KMT2C BAZ2A PHF3	5.01e-03	75	86	3	PF00628
Domain	-	SHROOM4 SYNPO2 CARD11 SHROOM2	5.10e-03	150	86	4	2.30.42.10
Domain	TPR-contain_dom	KLC2 TANC1 PPID ANAPC7	5.10e-03	150	86	4	IPR013026
Domain	PDZ	SHROOM4 SYNPO2 CARD11 SHROOM2	5.22e-03	151	86	4	PS50106
Domain	PDZ	SHROOM4 SYNPO2 CARD11 SHROOM2	5.34e-03	152	86	4	IPR001478
Domain	Znf_PHD-finger	KMT2C BAZ2A PHF3	5.79e-03	79	86	3	IPR019787
Domain	PAC	NCOA2 KCNH5	6.34e-03	26	86	2	IPR001610
Domain	PAC	NCOA2 KCNH5	6.34e-03	26	86	2	SM00086
Domain	TPR_REGION	KLC2 TANC1 PPID ANAPC7	7.11e-03	165	86	4	PS50293
Domain	TPR	KLC2 TANC1 PPID ANAPC7	7.11e-03	165	86	4	PS50005
Domain	PHD	KMT2C BAZ2A PHF3	8.05e-03	89	86	3	SM00249
Domain	UBA	MARK3 MARK4	8.38e-03	30	86	2	SM00165
Domain	Znf_PHD	KMT2C BAZ2A PHF3	8.56e-03	91	86	3	IPR001965
Domain	HMGI/Y_DNA-bd_CS	KMT2C BAZ2A	8.94e-03	31	86	2	IPR000637
Pathway	REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	NCOR2 MAML1 CREBBP MAML3	6.42e-06	28	62	4	M6177
Pathway	PID_RETINOIC_ACID_PATHWAY	NCOA2 NCOA3 NCOR2 CREBBP	8.53e-06	30	62	4	M207
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML1 CREBBP MAML3	2.85e-05	14	62	3	M27808
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION	NCOA2 NCOA3 NCOR2 MED13L CREBBP	3.30e-05	84	62	5	M1008
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS	MAML1 CREBBP MAML3	4.36e-05	16	62	3	M27121
Pathway	WP_NOTCH_SIGNALING_WP268	NCOR2 MAML1 CREBBP MAML3	4.42e-05	45	62	4	M39571
Pathway	WP_NOTCH_SIGNALING_PATHWAY	NCOR2 MAML1 CREBBP MAML3	4.82e-05	46	62	4	MM15971
Pathway	KEGG_NOTCH_SIGNALING_PATHWAY	NCOR2 MAML1 CREBBP MAML3	5.25e-05	47	62	4	M7946
Pathway	REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	NCOR2 MAML1 CREBBP MAML3	5.71e-05	48	62	4	M611
Pathway	REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 CREBBP MAML3	8.76e-05	20	62	3	M27881
Pathway	REACTOME_ADIPOGENESIS	NCOA2 NCOA3 NCOR2 MED13L CREBBP	1.20e-04	110	62	5	M48259
Pathway	REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER	NCOR2 MAML1 CREBBP MAML3	1.20e-04	58	62	4	M29616
Pathway	REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	NCOR2 MAML1 MAML3	1.35e-04	23	62	3	MM14954
Pathway	REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA	NCOA2 NCOA3 NCOR2 MED13L CREBBP	1.67e-04	118	62	5	M27316
Pathway	REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 CREBBP MAML3	1.74e-04	25	62	3	M27880
Pathway	BIOCARTA_RARRXR_PATHWAY	NCOA3 NCOR2	2.82e-04	6	62	2	MM1447
Pathway	REACTOME_SIGNALING_BY_NOTCH1	NCOR2 MAML1 CREBBP MAML3	3.10e-04	74	62	4	M616
Pathway	REACTOME_SIGNALING_BY_WNT	BCL9L CXXC4 TNRC6A XIAP MAP3K7 TRRAP CREBBP	5.89e-04	330	62	7	M7847
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	NCOA2 NCOA3 NCOR2 CREBBP	6.81e-04	91	62	4	M39700
Pathway	REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT	MAML1 CREBBP MAML3	8.23e-04	42	62	3	M17541
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	BRD2 MAML1 CREBBP MAML3	8.33e-04	96	62	4	M27784
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	MAML1 MAML3	8.37e-04	10	62	2	MM15535
Pathway	REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	NCOA2 NCOR2 CREBBP	9.44e-04	44	62	3	M27295
Pathway	KEGG_MEDICUS_REFERENCE_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY	NCOA2 NCOA3	1.02e-03	11	62	2	M47503
Pathway	PID_HES_HEY_PATHWAY	NCOR2 MAML1 CREBBP	1.22e-03	48	62	3	M288
Pathway	REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	MAML1 MAML3	1.22e-03	12	62	2	M27159
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00380	MAML1 MAML3	1.22e-03	12	62	2	M47532
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00381	MAML1 MAML3	1.22e-03	12	62	2	M47533
Pathway	REACTOME_SIGNALING_BY_NOTCH3	MAML1 CREBBP MAML3	1.29e-03	49	62	3	M618
Pathway	REACTOME_SUMOYLATION	NCOA2 NCOR2 NDC1 NR4A2 CREBBP	1.43e-03	189	62	5	M27214
Pathway	KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00382	MAML1 MAML3	1.44e-03	13	62	2	M47534
Pubmed	Human transcription factor protein interaction networks.	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C KLF12 MAP7D1 ZEB1 HIVEP1 BRD2 POLH SS18L1 TNRC6A SEC16A MAML1 N4BP1 EYA3 TRRAP SS18 CREBBP CNOT2 HP1BP3	9.53e-13	1429	89	23	35140242
Pubmed	Interaction network of human early embryonic transcription factors.	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 SS18L1 SEC16A MAML1 CREBBP	1.10e-10	351	89	12	38297188
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	NCOA2 TET2 NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 BRD2 SEC16A MAML1 PPID CREBBP	4.60e-10	398	89	12	35016035
Pubmed	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.	NCOA2 NCOA3 NCOR2 NR4A2 CREBBP	1.47e-09	20	89	5	11877444
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	NCOA2 TET2 BCL9L NCOA3 HIVEP1 PHF3 POLH MAML1 MED13L CREBBP	1.86e-09	268	89	10	33640491
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	NCOA2 BCL9L NCOA3 NCOR2 KMT2C NDC1 TNRC6A SEC16A MAML1 CREBBP MAML3 CNOT2	2.19e-09	457	89	12	32344865
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	SHISA9 NCOA2 NCOR2 KMT2C PDE4D MARK3 TOM1L1 GPATCH2 XIAP TNK2 NCAM2 AKAP13 TANC1 SHROOM2 TRRAP CREBBP MAML3 HP1BP3 ANKS1A	5.80e-09	1489	89	19	28611215
Pubmed	Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-beta geo cassette.	TET2 TRAF3IP2 NCOR2 KLF12 MARK3 TTLL4 TNRC6A TACC2 TANC1 MED13L CNOT2 TRAK1	1.29e-08	536	89	12	15840001
Pubmed	Exchangeable gene trap using the Cre/mutated lox system.	TET2 TRAF3IP2 NCOR2 KLF12 MARK3 TTLL4 TNRC6A TACC2 TANC1 MED13L CNOT2 TRAK1	1.34e-08	538	89	12	10512203
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	TET2 MAP7D1 HIVEP1 MARK3 PHF3 GTSE1 MARK4 SEC16A KLC2 XIAP AKAP13 TANC1 TRAK1 ANKS1A	4.00e-08	861	89	14	36931259
Pubmed	A human MAP kinase interactome.	KMT2C SYNPO2 HIVEP1 KIAA1549L TOM1L1 TNRC6A TNK2 AKAP13 MAP3K7 SS18 CREBBP	4.86e-08	486	89	11	20936779
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	NCOA3 NCOR2 MYOF ZEB1 HIVEP1 BRD2 BAZ2A PHF3 GTSE1 SEC16A KLC2 TRRAP ANKS1A	8.83e-08	774	89	13	15302935
Pubmed	Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.	NCOA2 NCOA3 NCOR2 CREBBP	9.29e-08	17	89	4	19183483
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	NCOR2 KMT2C MYOF BRD2 TTLL4 GTSE1 MARK4 SEC16A MAML1 TNK2 AKAP13 TANC1 MED13L TRRAP TRAK1	1.31e-07	1105	89	15	35748872
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	NCOA2 TET2 NCOA3 NCOR2 TNRC6A MAML1 CREBBP	1.35e-07	152	89	7	38360978
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	NCOR2 MAP7D1 BRD2 BAZ2A SS18L1 MARK4 TNRC6A SEC16A GPATCH2 XIAP TANC1 TRRAP SS18 ANAPC7 CREBBP	1.49e-07	1116	89	15	31753913
Pubmed	Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment.	NCOA2 NCOA3 CREBBP	1.61e-07	5	89	3	14766010
Pubmed	The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.	NCOA2 NCOA3 NCOR2	1.61e-07	5	89	3	10757795
Pubmed	Coactivator and corepressor gene expression in rat cerebellum during postnatal development and the effect of altered thyroid status.	NCOA2 NCOA3 NCOR2	1.61e-07	5	89	3	10803578
Pubmed	Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.	NCOA2 NCOA3 NCOR2 CREBBP	2.32e-07	21	89	4	19596656
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	NCOA2 KMT2C KLF12 HIVEP1 BRD2 BAZ2A NR4A2 XIAP TACC2 CREBBP MAML3 CNOT2	2.66e-07	709	89	12	22988430
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	NCOA2 NCOR2 HIVEP1 TNRC6A SEC16A MAML1 KLC2 TACC2 TANC1 EYA3 CREBBP	3.26e-07	588	89	11	38580884
Pubmed	cDNAs with long CAG trinucleotide repeats from human brain.	NCOA3 NCOR2 TNRC6A MAML3	3.42e-07	23	89	4	9225980
Pubmed	An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.	PHF3 TTLL4 TNRC6A SEC16A MAML1 AKAP13 N4BP1 TANC1 PPID CNOT2 ANKS1A SEPTIN2	3.79e-07	733	89	12	34672954
Pubmed	A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.	CHMP4C NCOA3 TTLL4 GTSE1 SEC16A GPATCH2 MAML1 DEPDC7 MAP3K7 ANAPC7 CNOT2 HP1BP3 TRAK1 SEPTIN2	3.89e-07	1038	89	14	26673895
Pubmed	BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.	NCOA2 NCOA3 CREBBP	5.63e-07	7	89	3	16860316
Pubmed	The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function.	NCOA2 NCOA3 CREBBP	5.63e-07	7	89	3	9192892
Pubmed	Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action.	NCOA2 NCOA3 NCOR2 CREBBP	7.83e-07	28	89	4	24880616
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	NCOA2 TET2 NCOA3 NCOR2 KMT2C MAP7D1 HIVEP1 MAML1 EYA3 MED13L TRRAP ANAPC7 CREBBP SEPTIN2	8.00e-07	1103	89	14	34189442
Pubmed	Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase.	NCOA2 NCOA3 CREBBP	8.99e-07	8	89	3	11971985
Pubmed	Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor γ (PPARγ) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes.	NCOA2 NCOA3 NCOR2	8.99e-07	8	89	3	23178929
Pubmed	Aberrant association of promyelocytic leukemia protein-retinoic acid receptor-alpha with coactivators contributes to its ability to regulate gene expression.	NCOA3 NCOR2 CREBBP	8.99e-07	8	89	3	17475621
Pubmed	Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.	NCOA2 NCOA3 CREBBP	8.99e-07	8	89	3	10490106
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	CRACD MAP7D1 BAZ2A MARK3 PHF3 MARK4 SEC16A MED13L TRAK1	1.05e-06	407	89	9	12693553
Pubmed	Spatiotemporal regulation of GLI target genes in the mammalian limb bud.	NCOR2 SDK2 NDC1 CXXC4 DEPDC7 PLPPR2 MAML3	1.09e-06	207	89	7	26238476
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	BCL9L CRACD KMT2C MYOF MAP7D1 BRD2 BAZ2A MARK3 PHF3 CXXC4 TNRC6A MAML1 TANC1 TRRAP ANAPC7 CNOT2	1.16e-06	1497	89	16	31527615
Pubmed	High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface.	TET2 MAP7D1 PTPRD GTSE1 TNRC6A SEC16A MAML1 CREBBP	1.28e-06	307	89	8	37499664
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	TET2 NCOA3 NCOR2 MAP7D1 ZEB1 HIVEP1 POLH TNRC6A SEC16A	1.31e-06	418	89	9	34709266
Pubmed	Transcriptional cofactors exhibit differential preference toward peroxisome proliferator-activated receptors alpha and delta in uterine cells.	NCOA2 NCOA3 NCOR2	1.92e-06	10	89	3	15001550
Pubmed	Identification of proximal SUMO-dependent interactors using SUMO-ID.	NCOA2 NCOR2 PHF3 GTSE1 SEC16A TACC2 EYA3 CREBBP SEPTIN2	2.14e-06	444	89	9	34795231
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	NCOA2 NCOA3 KMT2C MAP7D1 HIVEP1 PHF3 SHROOM2	2.39e-06	233	89	7	37704626
Pubmed	Tagging genes with cassette-exchange sites.	NCOA3 NCOR2 KMT2C GTSE1 AKAP13 TANC1 EYA3 CREBBP	2.44e-06	335	89	8	15741177
Pubmed	Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140.	NCOA2 NCOA3 CREBBP	4.55e-06	13	89	3	11266503
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	NDC1 TNRC6A SEC16A N4BP1 TANC1 FAM171B ANKS1A	5.30e-06	263	89	7	34702444
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	NCOA2 NCOA3 NCOR2 HIVEP1 SS18L1 MAML1 SS18 CREBBP TRIM64C MAML3	5.57e-06	638	89	10	31182584
Pubmed	Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins.	NCOA2 KMT2C CREBBP	5.78e-06	14	89	3	12482968
Pubmed	Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma.	TP63 XIAP	6.48e-06	2	89	2	18432259
Pubmed	Quantifying Protection in Disordered Proteins Using Millisecond Hydrogen Exchange-Mass Spectrometry and Peptic Reference Peptides.	NCOA3 CREBBP	6.48e-06	2	89	2	28675294
Pubmed	Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis.	NCOA2 NCOA3	6.48e-06	2	89	2	21220509
Pubmed	Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Distinct Entity Characterized by Recurrent NCOA2/3 Gene Fusions.	NCOA2 NCOA3	6.48e-06	2	89	2	30273195
Pubmed	Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX.	TET2 CXXC4	6.48e-06	2	89	2	23563267
Pubmed	Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.	TET2 KMT2C	6.48e-06	2	89	2	26880370
Pubmed	Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma.	TP63 XIAP	6.48e-06	2	89	2	18831009
Pubmed	A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells.	NCOA2 NCOA3	6.48e-06	2	89	2	30048685
Pubmed	Transforming growth factor-beta-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production.	CARD11 MAP3K7	6.48e-06	2	89	2	21771792
Pubmed	Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin.	NCOA3 CREBBP	6.48e-06	2	89	2	21632823
Pubmed	Immunohistochemical detection of p63 and XIAP in thymic hyperplasia and thymomas.	TP63 XIAP	6.48e-06	2	89	2	19369629
Pubmed	Common origin of the human synovial sarcoma associated SS18 and SS18L1 gene loci.	SS18L1 SS18	6.48e-06	2	89	2	16484776
Pubmed	Effects of a Levonorgestrel-Releasing Intrauterine System on the Expression of Steroid Receptor Coregulators in Adenomyosis.	NCOA2 NCOA3	6.48e-06	2	89	2	26040939
Pubmed	An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase.	BCL9L NCOA3 NCOR2 NDC1 TNRC6A SEC16A	7.20e-06	180	89	6	35198878
Pubmed	Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300.	NCOA3 NCOR2 CREBBP	7.21e-06	15	89	3	9267036
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	TET2 KMT2C SDK2 SRRM4 TTLL4 TNRC6A MAML1 ANKS1A SEPTIN2	8.80e-06	529	89	9	14621295
Pubmed	New nomenclature for chromatin-modifying enzymes.	NCOA2 NCOA3 KMT2C CREBBP	1.43e-05	57	89	4	18022353
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	NCOR2 KLF12 SYNPO2 TP63 GTSE1 TNK2 AKAP13 FAM186B	1.51e-05	430	89	8	35044719
Pubmed	Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling.	MAML1 MAML3	1.94e-05	3	89	2	12386158
Pubmed	Dendrite development regulated by CREST, a calcium-regulated transcriptional activator.	SS18L1 CREBBP	1.94e-05	3	89	2	14716005
Pubmed	The transcriptional coregulators TIF2 and SRC-1 regulate energy homeostasis by modulating mitochondrial respiration in skeletal muscles.	NCOA2 NCOA3	1.94e-05	3	89	2	21035760
Pubmed	Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.	NCOA2 NCOA3	1.94e-05	3	89	2	21059860
Pubmed	Siva1 is a XIAP-interacting protein that balances NFkappaB and JNK signalling to promote apoptosis.	XIAP MAP3K7	1.94e-05	3	89	2	19584092
Pubmed	Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.	NCOA2 NCOA3	1.94e-05	3	89	2	21735116
Pubmed	Absence of the steroid receptor coactivator-3 induces B-cell lymphoma.	NCOA2 NCOA3	1.94e-05	3	89	2	16675958
Pubmed	FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors.	NCOA2 NCOA3	1.94e-05	3	89	2	15698540
Pubmed	Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene.	NCOA2 NCOA3	1.94e-05	3	89	2	9506940
Pubmed	Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex.	MAML1 CREBBP	1.94e-05	3	89	2	12050117
Pubmed	Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers.	NCOA2 NCOA3	1.94e-05	3	89	2	28390937
Pubmed	Long non-coding RNA SNHG1 regulates zinc finger E-box binding homeobox 1 expression by interacting with TAp63 and promotes cell metastasis and invasion in Lung squamous cell carcinoma.	ZEB1 TP63	1.94e-05	3	89	2	28415044
Pubmed	Structure of Slitrk2-PTPδ complex reveals mechanisms for splicing-dependent trans-synaptic adhesion.	SLITRK2 PTPRD	1.94e-05	3	89	2	25989451
Pubmed	XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway.	XIAP MAP3K7	1.94e-05	3	89	2	9878061
Pubmed	Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression.	NCOA2 NCOA3	1.94e-05	3	89	2	19277704
Pubmed	Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences.	NCOA2 NCOA3	1.94e-05	3	89	2	23927929
Pubmed	Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation.	NCOA2 NCOA3	1.94e-05	3	89	2	19052561
Pubmed	Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance.	NCOA2 NCOR2	1.94e-05	3	89	2	11518802
Pubmed	Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators.	NCOA3 CREBBP	1.94e-05	3	89	2	11823864
Pubmed	Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.	NCOA2 NCOA3	1.94e-05	3	89	2	18845648
Pubmed	The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP.	NCOA2 NCOA3	1.94e-05	3	89	2	12138202
Pubmed	deltaEF1 repressor controls selectively p53 family members during differentiation.	ZEB1 TP63	1.94e-05	3	89	2	16007124
Pubmed	The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1.	NCOA2 NCOA3	1.94e-05	3	89	2	11923473
Pubmed	Structure and chromosomal locations of mouse steroid receptor coactivator gene family.	NCOA2 NCOA3	1.94e-05	3	89	2	10501088
Pubmed	Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression.	SS18L1 SS18	1.94e-05	3	89	2	16926188
Pubmed	ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma.	ZEB1 TP63	1.94e-05	3	89	2	26864590
Pubmed	Mapping and characterization of the mouse and human SS18 genes, two human SS18-like genes and a mouse Ss18 pseudogene.	SS18L1 SS18	1.94e-05	3	89	2	11435705
Pubmed	Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor.	CARD11 MAP3K7	1.94e-05	3	89	2	20064449
Pubmed	The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism.	NCOA2 NCOA3	1.94e-05	3	89	2	16423883
Pubmed	Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.	NCOR2 MYOF NDC1 BRD2 MARK3 GPATCH2 TNK2 MAP3K7 TRRAP ANAPC7 CREBBP	2.11e-05	910	89	11	36736316
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	NCOA2 TET2 ZNF34 PTPRD BRD2 NR4A2 NCAM2 EYA3 MED13L SHROOM2 CREBBP CNOT2 SEPTIN2	2.33e-05	1285	89	13	35914814
Pubmed	HSF1 phosphorylation establishes an active chromatin state via the TRRAP-TIP60 complex and promotes tumorigenesis.	BCL9L NCOR2 MYOF NDC1 SEC16A TRRAP ANAPC7 CREBBP ARHGEF15 ANKS1A	2.35e-05	754	89	10	35906200
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	KMT2C MYOF PHF3 SEC16A MED13L ARHGEF15	2.55e-05	225	89	6	12168954
Pubmed	The in vivo Interaction Landscape of Histones H3.1 and H3.3.	HIVEP1 BRD2 BAZ2A PHF3 POLH EYA3 TRRAP ANAPC7 HP1BP3	2.64e-05	608	89	9	36089195
Pubmed	Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells.	NCOA2 NCOA3 NCOR2	2.76e-05	23	89	3	19737349
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	NCOR2 HIVEP1 BRD2 BAZ2A PHF3 POLH SS18L1 GTSE1 SEC16A SS18 HP1BP3	3.25e-05	954	89	11	36373674
Interaction	SP7 interactions	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C HIVEP1 POLH SS18L1 MAML1 N4BP1 EYA3 SS18 CREBBP	6.48e-11	304	89	14	int:SP7
Interaction	EGR2 interactions	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C HIVEP1 SS18L1 SEC16A MAML1 CREBBP	2.45e-10	171	89	11	int:EGR2
Interaction	ERG interactions	NCOA2 TET2 NCOA3 NCOR2 KMT2C HIVEP1 PTPRD BRD2 SS18L1 MAML1 SS18 CREBBP	2.81e-10	223	89	12	int:ERG
Interaction	HNF1B interactions	NCOA2 TET2 NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 POLH MAML1 TRRAP CREBBP	7.54e-10	190	89	11	int:HNF1B
Interaction	KLF5 interactions	NCOA2 TET2 NCOA3 NCOR2 KMT2C HIVEP1 TP63 SEC16A MAML1 SS18 CREBBP	9.93e-10	195	89	11	int:KLF5
Interaction	PAX8 interactions	NCOA2 TET2 NCOA3 NCOR2 KMT2C HIVEP1 SS18L1 MAML1 CREBBP	1.48e-09	111	89	9	int:PAX8
Interaction	TBR1 interactions	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C HIVEP1 BRD2 MAML1	1.73e-09	113	89	9	int:TBR1
Interaction	TBXT interactions	NCOA2 NCOA3 NCOR2 KMT2C HIVEP1 SS18L1 MAML1 SS18 CREBBP	2.19e-09	116	89	9	int:TBXT
Interaction	YWHAG interactions	CHMP4C TET2 CRACD SYNPO2 MAP7D1 HIVEP1 MARK3 PHF3 GTSE1 MARK4 SEC16A KLC2 XIAP TNK2 NCAM2 AKAP13 TANC1 SHROOM2 TRRAP SS18 TRAK1 ANKS1A PYHIN1	3.03e-09	1248	89	23	int:YWHAG
Interaction	PAX7 interactions	NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 SS18L1 MAML1 SS18 CREBBP	3.96e-09	124	89	9	int:PAX7
Interaction	TLE3 interactions	NCOA2 TET2 TRAF3IP2 BCL9L NCOA3 NCOR2 HIVEP1 POLH TNRC6A MAML1 XIAP EYA3 CREBBP	1.06e-08	376	89	13	int:TLE3
Interaction	MYOD1 interactions	NCOA2 NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 SS18L1 TRRAP SS18 CREBBP	1.42e-08	194	89	10	int:MYOD1
Interaction	GCM1 interactions	TET2 NCOA3 NCOR2 KMT2C HIVEP1 SS18 CREBBP	2.01e-08	68	89	7	int:GCM1
Interaction	ETV4 interactions	NCOA2 NCOA3 NCOR2 TP63 SEC16A SS18 CREBBP	2.23e-08	69	89	7	int:ETV4
Interaction	KLF15 interactions	NCOA2 NCOA3 NCOR2 KMT2C MAP7D1 HIVEP1 SEC16A MAML1 CREBBP HP1BP3 ANKS1A	6.12e-08	290	89	11	int:KLF15
Interaction	SOX7 interactions	NCOA2 TET2 NCOA3 NCOR2 KMT2C MAML1 CREBBP	7.49e-08	82	89	7	int:SOX7
Interaction	TLX1 interactions	NCOA2 NCOA3 NCOR2 KMT2C HIVEP1 MAML1 EYA3 CREBBP HP1BP3	8.00e-08	175	89	9	int:TLX1
Interaction	YWHAH interactions	NCOA2 TET2 NCOA3 MAP7D1 HIVEP1 MARK3 PHF3 GTSE1 MARK4 SEC16A KLC2 NCAM2 AKAP13 TANC1 MAP3K7 CREBBP TRAK1 ANKS1A PYHIN1	2.63e-07	1102	89	19	int:YWHAH
Interaction	FEV interactions	NCOA2 NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 SS18L1 MAML1 CREBBP	2.83e-07	203	89	9	int:FEV
Interaction	NUP35 interactions	NCOA2 BCL9L NCOA3 NCOR2 KMT2C NDC1 TNRC6A SEC16A MAML1 CREBBP MAML3 CNOT2	3.54e-07	424	89	12	int:NUP35
Interaction	HNF4A interactions	NCOA2 NCOA3 NCOR2 KMT2C HIVEP1 BRD2 SS18L1 TRRAP SS18 CREBBP	3.75e-07	275	89	10	int:HNF4A
Interaction	TLX3 interactions	NCOA2 TET2 BCL9L NCOA3 ZNF34 NCOR2 KMT2C HIVEP1 MAML1 EYA3	6.28e-07	291	89	10	int:TLX3
Interaction	FOS interactions	NCOA2 NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 SS18L1 MAP3K7 SS18 CREBBP	1.18e-06	312	89	10	int:FOS
Interaction	AR interactions	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C HIVEP1 BRD2 PHF3 POLH SEC16A MAML1 TNK2 MED13L TRRAP PPID CREBBP	1.36e-06	992	89	17	int:AR
Interaction	NFIA interactions	NCOA2 NCOA3 NCOR2 KLF12 HIVEP1 MAML1 CREBBP HP1BP3	1.83e-06	188	89	8	int:NFIA
Interaction	CRX interactions	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C SS18L1 MAML1 CREBBP	1.84e-06	254	89	9	int:CRX
Interaction	KLF8 interactions	NCOA2 NCOA3 NCOR2 MAP7D1 ZEB1 HIVEP1 BRD2 TP63 SEC16A CREBBP	1.91e-06	329	89	10	int:KLF8
Interaction	NOTCH4 interactions	MAML1 MAP3K7 TRRAP MAML3	2.01e-06	21	89	4	int:NOTCH4
Interaction	GSC interactions	BCL9L NCOA3 NCOR2 KMT2C HIVEP1 CREBBP	2.37e-06	87	89	6	int:GSC
Interaction	NFIB interactions	NCOA3 NCOR2 KMT2C KLF12 HIVEP1 MAML1 CREBBP	3.16e-06	142	89	7	int:NFIB
Interaction	SMARCA4 interactions	NCOR2 ZEB1 BRD2 SS18L1 MARK4 NR4A2 MAML1 TRRAP SS18 CREBBP PYHIN1	5.96e-06	462	89	11	int:SMARCA4
Interaction	YWHAE interactions	CHMP4C TET2 CRACD NCOR2 MAP7D1 HIVEP1 MARK3 GTSE1 MARK4 KLC2 NCAM2 AKAP13 TACC2 TANC1 SHROOM2 MAP3K7 TRAK1 ANKS1A	7.85e-06	1256	89	18	int:YWHAE
Interaction	LHX4 interactions	NCOA2 BCL9L MAPRE3 NCOR2 KMT2C HIVEP1 TRRAP	8.86e-06	166	89	7	int:LHX4
Interaction	SH3KBP1 interactions	TCP10L CHMP4C HIVEP1 TP63 GTSE1 KLC2 ANAPC7 ANKS1A SEPTIN2	1.06e-05	315	89	9	int:SH3KBP1
Interaction	SOX2 interactions	NCOA2 TET2 BCL9L NCOA3 NCOR2 KMT2C ZEB1 PDE4D HIVEP1 MARK3 TP63 TNRC6A SEC16A MAML1 CEP170P1 MED13L SS18 ANAPC7 SEPTIN2	1.14e-05	1422	89	19	int:SOX2
Interaction	SMG7 interactions	NCOA2 NCOA3 NCOR2 HIVEP1 TNRC6A SEC16A MAML1 CREBBP CNOT2	1.17e-05	319	89	9	int:SMG7
Interaction	CREBBP interactions	NCOA2 NCOA3 NCOR2 ZEB1 HIVEP1 SS18L1 MAML1 TACC2 TRRAP ANAPC7 CREBBP ANKS1A	1.25e-05	599	89	12	int:CREBBP
Interaction	TEAD1 interactions	NCOR2 KMT2C ZEB1 HIVEP1 TP63 TRRAP CREBBP	1.30e-05	176	89	7	int:TEAD1
Interaction	PML interactions	NCOA2 TET2 NCOR2 PHF3 TP63 GTSE1 SEC16A XIAP TACC2 EYA3 ANAPC7 CREBBP HP1BP3 PYHIN1 SEPTIN2	1.32e-05	933	89	15	int:PML
Interaction	YWHAZ interactions	CHMP4C TET2 CRACD SYNPO2 MAP7D1 PDE4D HIVEP1 MARK3 PHF3 MARK4 KLC2 TNK2 NCAM2 AKAP13 TACC2 TANC1 TRAK1 ANKS1A	1.53e-05	1319	89	18	int:YWHAZ
Interaction	FBXO42 interactions	NCOR2 HIVEP1 TNRC6A SEC16A KLC2 TACC2 TANC1 MAP3K7	1.92e-05	259	89	8	int:FBXO42
Interaction	PAX9 interactions	NCOA2 BCL9L NCOA3 NCOR2 KMT2C MAML1	2.41e-05	130	89	6	int:PAX9
Interaction	GATA2 interactions	NCOA3 NCOR2 KMT2C ZEB1 HIVEP1 SS18 CREBBP	2.86e-05	199	89	7	int:GATA2
Interaction	E2F1 interactions	NCOA3 NCOR2 BRD2 XIAP TRRAP ANAPC7 CREBBP	2.96e-05	200	89	7	int:E2F1
Interaction	NCOA6 interactions	NCOA2 NCOR2 KMT2C TNRC6A XIAP CREBBP	4.45e-05	145	89	6	int:NCOA6
Interaction	PYGO2 interactions	BCL9L KLC2 TRRAP CREBBP	5.96e-05	48	89	4	int:PYGO2
Interaction	NR1I2 interactions	NCOA2 NCOA3 NCOR2 TRRAP	5.96e-05	48	89	4	int:NR1I2
Interaction	CHUK interactions	TRAF3IP2 NCOA3 NCOR2 TP63 CARD11 MAP3K7 CREBBP	6.07e-05	224	89	7	int:CHUK
Interaction	SOX17 interactions	NCOA2 NCOA3 NCOR2 KMT2C SS18	6.36e-05	95	89	5	int:SOX17
Interaction	EYA4 interactions	NCOA2 TET2 NCOA3 NCOR2 TNRC6A MAML1 CREBBP	1.01e-04	243	89	7	int:EYA4
Interaction	MYH9 interactions	TET2 NCOA3 HIVEP1 PHF3 TP63 GTSE1 MARK4 SEC16A TNK2 TRRAP WDFY4 CREBBP	1.17e-04	754	89	12	int:MYH9
Interaction	THRA interactions	NCOA2 NCOA3 NCOR2 AKAP13 CREBBP	1.33e-04	111	89	5	int:THRA
Interaction	YWHAB interactions	CHMP4C TET2 MAP7D1 HIVEP1 MARK3 PHF3 MARK4 KLC2 NCAM2 AKAP13 TANC1 TRRAP TRAK1 ANKS1A	1.37e-04	1014	89	14	int:YWHAB
Interaction	KAT2B interactions	NCOA3 KLF12 ZEB1 TP63 TACC2 TRRAP CREBBP	1.40e-04	256	89	7	int:KAT2B
Interaction	SMARCD1 interactions	TCP10L ZNF438 BRD2 SS18L1 TNRC6A SS18 WDFY4 ANKS1A	1.56e-04	349	89	8	int:SMARCD1
Interaction	NR6A1 interactions	NCOR2 TRRAP CREBBP	1.58e-04	24	89	3	int:NR6A1
Interaction	EGLN3 interactions	NCOA2 TET2 NCOR2 NDC1 PHF3 TTLL4 GTSE1 SEC16A GPATCH2 MAML1 AKAP13 EYA3 MAP3K7 ANAPC7 CREBBP CNOT2	1.59e-04	1296	89	16	int:EGLN3
Interaction	LHX2 interactions	BCL9L NCOR2 KMT2C HIVEP1 SS18 ANKS1A	1.61e-04	183	89	6	int:LHX2
Interaction	NCOR2 interactions	NCOA3 NCOR2 SEC16A NR4A2 TRRAP CREBBP CNOT2	1.69e-04	264	89	7	int:NCOR2
Interaction	BRD9 interactions	BRD2 SS18L1 CXXC4 TRRAP SS18	1.70e-04	117	89	5	int:BRD9
Interaction	RXRB interactions	NCOA3 NR4A2 AKAP13 TACC2	2.08e-04	66	89	4	int:RXRB
Interaction	SFN interactions	CHMP4C TET2 MAP7D1 MARK3 PHF3 TP63 KLC2 AKAP13 TANC1 TRAK1 ANKS1A	2.31e-04	692	89	11	int:SFN
Interaction	ARX interactions	GTSE1 SEC16A KLC2	2.52e-04	28	89	3	int:ARX
Interaction	MARF1 interactions	MAPRE3 GTSE1 TNRC6A N4BP1 CREBBP	2.59e-04	128	89	5	int:MARF1
Interaction	CCDC6 interactions	TCP10L TNRC6A SEC16A KLC2 CEP170P1 TANC1 SEPTIN2	2.75e-04	286	89	7	int:CCDC6
Interaction	SMARCE1 interactions	NCOA2 NCOA3 BRD2 SS18L1 CEP170P1 TRRAP SS18	2.81e-04	287	89	7	int:SMARCE1
Interaction	SLITRK1 interactions	CHMP4C PTPRD	2.86e-04	6	89	2	int:SLITRK1
Interaction	KCNE3 interactions	MYOF MAP7D1 BRD2 TOM1L1 GTSE1 MARK4 MAP3K7	3.39e-04	296	89	7	int:KCNE3
Interaction	CEBPA interactions	NCOA2 TET2 NCOA3 NCOR2 KMT2C MAP7D1 HIVEP1 MAML1 EYA3 MED13L TRRAP ANAPC7 CREBBP HP1BP3 SEPTIN2	3.40e-04	1245	89	15	int:CEBPA
Interaction	GOLGA2 interactions	ZNF438 NCOA2 TRAF3IP2 MAPRE3 NCOR2 HIVEP1 GTSE1 SEC16A XIAP TRAK1 ANKS1A	3.78e-04	733	89	11	int:GOLGA2
Interaction	PPARG interactions	NCOA2 NCOA3 NCOR2 KMT2C HIVEP1 NR4A2 CREBBP	4.21e-04	307	89	7	int:PPARG
Interaction	IFNAR2 interactions	PDE4D XIAP CREBBP	4.51e-04	34	89	3	int:IFNAR2
Interaction	H3-3A interactions	KMT2C HIVEP1 BRD2 BAZ2A PHF3 POLH EYA3 TRRAP ANAPC7 CREBBP HP1BP3	4.53e-04	749	89	11	int:H3-3A
Interaction	CDK8 interactions	HIVEP1 SEC16A MAML1 MED13L TRRAP CREBBP	4.53e-04	222	89	6	int:CDK8
Interaction	FBXO38 interactions	NCOR2 HIVEP1 MAML1 TRRAP CREBBP	4.60e-04	145	89	5	int:FBXO38
Interaction	MDC1 interactions	CHMP4C BRD2 PHF3 TNRC6A TRRAP ANAPC7 CREBBP PYHIN1	4.90e-04	414	89	8	int:MDC1
Interaction	NFIX interactions	NCOR2 KMT2C ZEB1 HIVEP1 BRD2 TRRAP	5.10e-04	227	89	6	int:NFIX
Interaction	CEP170 interactions	MAPRE3 MAP7D1 BRD2 GTSE1 CEP170P1 XIAP TNK2	5.20e-04	318	89	7	int:CEP170
Interaction	MAPRE3 interactions	MAPRE3 MAP7D1 MARK3 GTSE1 TACC2 TANC1	5.46e-04	230	89	6	int:MAPRE3
Interaction	PAX2 interactions	NCOA3 NCOR2 KMT2C HIVEP1	5.48e-04	85	89	4	int:PAX2
Interaction	IRF4 interactions	NCOA3 NCOR2 KMT2C SS18	5.48e-04	85	89	4	int:IRF4
Interaction	IKBKB interactions	TRAF3IP2 NCOA3 TP63 SEC16A MAP3K7 CREBBP	5.85e-04	233	89	6	int:IKBKB
Interaction	PPP1R13L interactions	MAPRE3 GTSE1 SEC16A CREBBP	6.25e-04	88	89	4	int:PPP1R13L
Interaction	TNK1 interactions	SS18L1 GTSE1 SEC16A	6.28e-04	38	89	3	int:TNK1
Interaction	DTX2 interactions	BCL9L NCOA3 ZNF34 NCOR2 NDC1 TNRC6A SEC16A	6.47e-04	330	89	7	int:DTX2
Interaction	TOP3B interactions	NCOR2 KMT2C MYOF BRD2 TTLL4 GTSE1 MARK4 SEC16A MAML1 TNK2 AKAP13 TANC1 MED13L TRRAP CNOT2 TRAK1	6.48e-04	1470	89	16	int:TOP3B
Interaction	PPARA interactions	NCOA2 NCOA3 NCOR2 AKAP13	7.38e-04	92	89	4	int:PPARA
Interaction	SOX10 interactions	NCOA2 NCOA3 NCOR2 HIVEP1	7.38e-04	92	89	4	int:SOX10
Interaction	FOXI1 interactions	NCOA3 NCOR2 KMT2C CREBBP	7.38e-04	92	89	4	int:FOXI1
Interaction	TERF2IP interactions	NCOA2 NCOR2 ZEB1 HIVEP1 BAZ2A PHF3 EYA3 CREBBP HP1BP3	7.39e-04	552	89	9	int:TERF2IP
GeneFamily	Ataxins\|Trinucleotide repeat containing	NCOA3 NCOR2 TNRC6A MAML3	8.58e-07	25	54	4	775
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	NCOA2 NCOA3 CREBBP	1.66e-05	17	54	3	486
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	KLC2 TANC1 PPID ANAPC7	3.84e-04	115	54	4	769
GeneFamily	PDZ domain containing	SHROOM4 SYNPO2 CARD11 SHROOM2	1.10e-03	152	54	4	1220
GeneFamily	PHD finger proteins	KMT2C BAZ2A PHF3	2.46e-03	90	54	3	88
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	NCOA2 NCOA3 NCOR2 MYOF ZEB1 HIVEP1 MARK3 PHF3 AKAP13 N4BP1 MED13L TRRAP CREBBP CNOT2 TRAK1 ANKS1A	2.34e-08	856	88	16	M4500
Coexpression	GSE5503_MLN_DC_VS_PLN_DC_ACTIVATED_ALLOGENIC_TCELL_DN	TRAF3IP2 ZEB1 POLH TNRC6A MAML1 AKAP13 MED13L CREBBP	3.81e-07	200	88	8	M291
Coexpression	SCHEIDEREIT_IKK_INTERACTING_PROTEINS	TRAF3IP2 NCOA3 CARD11 MAP3K7 CREBBP	9.61e-07	53	88	5	M6303
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	TET2 KMT2C ZEB1 BAZ2A TTLL4 PWWP3B CREBBP	2.55e-06	180	88	7	M8239
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	NCOA3 HIVEP1 MARK3 PHF3 MED13L TRRAP CREBBP CNOT2 TRAK1 ANKS1A	3.75e-06	466	88	10	M13522
Coexpression	DAZARD_RESPONSE_TO_UV_NHEK_DN	NCOA3 PHF3 TP63 MAML1 N4BP1 MED13L CREBBP CNOT2	7.80e-06	300	88	8	M8702
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	NCOA3 KMT2C KLF12 MAP7D1 ZEB1 MARK3 PHF3 NR4A2 XIAP TNK2 AKAP13 CARD11 N4BP1 CREBBP CNOT2 PYHIN1 SEPTIN2	8.22e-06	1492	88	17	M40023
Coexpression	GSE15624_CTRL_VS_3H_HALOFUGINONE_TREATED_CD4_TCELL_UP	TET2 NCOA3 ZEB1 BRD2 SEC16A N4BP1	1.69e-05	160	88	6	M7116
Coexpression	GSE7509_UNSTIM_VS_FCGRIIB_STIM_MONOCYTE_DN	TET2 PTPRD BAZ2A TTLL4 TNRC6A TRAK1	2.08e-05	166	88	6	M6826
Coexpression	FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP	NCOA2 NCOA3 MYOF ZEB1 PTPRD PHF3 N4BP1 TRRAP PPID CREBBP	2.09e-05	568	88	10	M4023
Coexpression	DAZARD_RESPONSE_TO_UV_SCC_DN	MARK3 PHF3 TP63 N4BP1 CNOT2	4.37e-05	115	88	5	M7484
Coexpression	GSE18893_TCONV_VS_TREG_2H_TNF_STIM_DN	TET2 BRD2 AKAP13 MED13L CREBBP TRAK1	4.98e-05	194	88	6	M7306
Coexpression	GSE3691_IFN_PRODUCING_KILLER_DC_VS_PLASMACYTOID_DC_SPLEEN_UP	MARK3 SS18L1 CARD11 N4BP1 CREBBP TRAK1	5.90e-05	200	88	6	M6367
Coexpression	GSE16385_ROSIGLITAZONE_IL4_VS_IFNG_TNF_STIM_MACROPHAGE_UP	NCOA3 HIVEP1 MARK3 NR4A2 MAML1 CREBBP	5.90e-05	200	88	6	M8030
Coexpression	BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP	NCOA3 KLF12 HIVEP1 BRD2 BAZ2A MARK3 PHF3 XIAP N4BP1 MED13L CREBBP	9.59e-05	822	88	11	M6782
Coexpression	FOSTER_TOLERANT_MACROPHAGE_DN	TET2 TRAF3IP2 ZEB1 PTPRD N4BP1 TANC1 MED13L PYHIN1	1.09e-04	435	88	8	MM1221
Coexpression	LAKE_ADULT_KIDNEY_C27_VASCULAR_SMOOTH_MUSCLE_CELLS_AND_PERICYTES	SYNPO2 ZEB1 AKAP13 MED13L MAML3	1.79e-04	155	88	5	M39246
Coexpression	HE_LIM_SUN_FETAL_LUNG_C1_GHRL_POS_NEUROENDOCRINE_CELL	MMRN1 MAPRE3 SRRM4 CXXC4 PLPPR2	1.79e-04	155	88	5	M45695
CoexpressionAtlas	FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_2500_k-means-cluster#5	TET2 MAPRE3 KMT2C KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 AKAP13 FAM171B PLPPR2 TRAK1	1.15e-06	722	86	14	Facebase_RNAseq_e9.5_Facial Mesenchyne_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#2	TET2 MAPRE3 KMT2C KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 AKAP13 FAM171B PLPPR2 TRAK1	1.71e-06	747	86	14	Facebase_RNAseq_e9.5_Maxillary Arch_2500_K2
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#4	TET2 MAPRE3 KMT2C KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 FAM171B PLPPR2 TRAK1	6.35e-06	721	86	13	Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_2500_K4
CoexpressionAtlas	FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_2500_k-means-cluster#1	NCOA2 TET2 MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 CXXC4 NCAM2 FAM171B PLPPR2	6.67e-06	614	86	12	Facebase_RNAseq_e10.5_Medial Nasal Eminence_2500_K1
CoexpressionAtlas	FacebaseRNAseq_e8.5_Paraxial Mesoderm_top-relative-expression-ranked_2500_k-means-cluster#3	TET2 MAPRE3 KMT2C KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 FAM171B PLPPR2 TRAK1	7.26e-06	730	86	13	Facebase_RNAseq_e8.5_Paraxial Mesoderm_2500_K3
CoexpressionAtlas	FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#5	TET2 MAPRE3 KMT2C KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 FAM171B PLPPR2 TRAK1	8.77e-06	743	86	13	Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_2500_K5
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_top-relative-expression-ranked_500	KLF12 SYNPO2 SLITRK2 PHF3 TP63 CXXC4 XIAP NCAM2 FAM171B MAP3K7	8.82e-06	427	86	10	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_500
CoexpressionAtlas	FacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_2500_k-means-cluster#2	TET2 CRACD MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NCAM2 FAM171B PLPPR2 TRAK1	1.35e-05	659	86	12	Facebase_RNAseq_e10.5_Olfactory Pit_2500_K2
CoexpressionAtlas	FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#5	TET2 MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 FAM171B PLPPR2 TRAK1	3.80e-05	732	86	12	Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_2500_K5
CoexpressionAtlas	FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#2	TET2 MAPRE3 KMT2C KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NCAM2 FAM171B PLPPR2 TRAK1	4.63e-05	747	86	12	Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_2500_K2
CoexpressionAtlas	FacebaseRNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#5	TET2 MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 FAM171B PLPPR2	6.91e-05	658	86	11	Facebase_RNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#5	TET2 MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NCAM2 FAM171B PLPPR2 TRAK1	1.03e-04	688	86	11	Facebase_RNAseq_e10.5_Mandibular Arch_2500_K5
CoexpressionAtlas	FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_2500_k-means-cluster#3	MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 CXXC4 NR4A2 NCAM2 FAM171B PLPPR2 TRAK1	2.48e-04	893	86	12	Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_2500_K3
CoexpressionAtlas	facebase_RNAseq_e14.5_palate_poster_proximal_ERK2_WT_2500_K2	TET2 BCL9L MAPRE3 NCOR2 SYNPO2 SDK2 PDE4D PTPRD KIAA1549L SEC16A NR4A2 PWWP3B FAM171B PLPPR2	3.35e-04	1208	86	14	facebase_RNAseq_e14.5_palate_poster_proximal_ERK2_WT_2500_K2
CoexpressionAtlas	facebase_RNAseq_e10.5_NeuroEpith_central_2500_K4	NCOA2 CRACD KLF12 ZEB1 NDC1 KIAA1549L PHF3 TTLL4 CXXC4 KLC2 PWWP3B FAM171B SHROOM2 TRAK1 KCNH5	3.68e-04	1370	86	15	facebase_RNAseq_e10.5_NeuroEpith_central_2500_K4
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_k-means-cluster#2_top-relative-expression-ranked_1000	KLF12 PHF3 XIAP NCAM2 FAM171B MAP3K7 CREBBP	3.86e-04	330	86	7	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_k2_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_2500_k-means-cluster#4	MAPRE3 KLF12 PTPRD KIAA1549L SRRM4 SS18L1 NR4A2 NCAM2 FAM171B PLPPR2	4.35e-04	683	86	10	Facebase_RNAseq_e9.5_Olfactory Placode_2500_K4
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_top-relative-expression-ranked_1000	KLF12 SYNPO2 SLITRK2 PHF3 TP63 CXXC4 XIAP NCAM2 FAM171B MAP3K7 CREBBP	4.55e-04	818	86	11	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_1000
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SHROOM4 SYNPO2 SLITRK2 ZEB1 TANC1 SHROOM2 ARHGEF15	1.10e-07	190	89	7	0a351609a72fd638c84b2435782e312ee6a33aac
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NCOA2 KMT2C PDE4D AKAP13 MED13L MAML3	2.49e-06	193	89	6	779276e775cb2492e8dd36436295a536084a6415
ToppCell	IPF-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	CRACD SDK2 PDE4D PTPRD NCAM2 TANC1	2.81e-06	197	89	6	f304d42fc4936fe20996e07c8dccc698a6e5e5ef
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 PDE4D PTPRD TANC1 MED13L MAML3	2.89e-06	198	89	6	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 KMT2C PDE4D TNRC6A MED13L MAML3	2.97e-06	199	89	6	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	COVID-19\|World / Disease, condition lineage and cell class	KMT2C PDE4D PHF3 AKAP13 N4BP1 MED13L	3.06e-06	200	89	6	7dec470c379cd89f05a0f37c8628b21f136e52f0
ToppCell	BAL-Control-Lymphocyte-T/NK-NK_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MMRN1 KLF12 SDK2 ZEB1 PTPRD	2.14e-05	167	89	5	94642b3dae035fedb6e8b9745f440096a4539f3c
ToppCell	BAL-Control-Lymphocyte-T/NK-NK_cell-NK\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	MMRN1 KLF12 SDK2 ZEB1 PTPRD	2.14e-05	167	89	5	42b299273a6c72a625b204d55f4f3c4eebd6d185
ToppCell	BAL-Control-Lymphocyte-T/NK-NK_cell-NK-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MMRN1 KLF12 SDK2 ZEB1 PTPRD	2.14e-05	167	89	5	ecf5bc634e1e01efd783617eb81d1704e903ea21
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MYOF SYNPO2 SDK2 NR4A2 KCNH5	2.61e-05	174	89	5	e4d65fe121a32ac4cdd6312e7b8f867f0852e991
ToppCell	Control-T/NK-NK\|Control / Disease group,lineage and cell class （2021.01.30）	MMRN1 KLF12 SDK2 ZEB1 PTPRD	2.91e-05	178	89	5	079fd19bdeed86bf985c4083af432432d66ad546
ToppCell	IPF-Lymphoid-B\|World / Disease state, Lineage and Cell class	NCOA3 SDK2 ZEB1 CARD11 WDFY4	3.07e-05	180	89	5	30f9398c9b784f49470847a025bac90687e997a1
ToppCell	COVID-19-Endothelial_cells-Capillary_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	SHROOM4 ZEB1 ITPRID1 SHROOM2 ARHGEF15	3.15e-05	181	89	5	c5f9c92af1384d9089c65afdf41c6feb8345a3ae
ToppCell	nucseq-Immune-Lymphocytic_B-Lymphocytic_B-B\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NCOA3 KLF12 ZEB1 CARD11 WDFY4	3.15e-05	181	89	5	8d8cc4dae2c8bd5f4b1c159f2a52edc4c9449c86
ToppCell	10x3'2.3-week_12-13-Mesenchymal_myocytic-stroma-muscle\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	CHMP4C SDK2 TANC1 PWWP3B DEPDC7	3.49e-05	185	89	5	0094f9baddb20214d2a2c166f1637d1a9cf1169a
ToppCell	saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLF12 ZEB1 PDE4D CARD11 PYHIN1	3.49e-05	185	89	5	f1263899a2d41d182022dc4ca62cbae08a463c89
ToppCell	COPD-Lymphoid-B\|World / Disease state, Lineage and Cell class	NCOA3 KLF12 ZEB1 CARD11 WDFY4	3.49e-05	185	89	5	22891ed75e25ef30dfa541cb82d85e08ce07e7d9
ToppCell	COVID-19-Endothelial_cells-Pulmonary_venous_endothelial_cells\|COVID-19 / group, cell type (main and fine annotations)	MMRN1 SHROOM4 ZEB1 KIAA1549L SHROOM2	3.68e-05	187	89	5	2d20193a6cacdfa4877457c97b0077408942186c
ToppCell	COPD-Multiplet-Multiplet\|World / Disease state, Lineage and Cell class	KLF12 PDE4D CARD11 TACC2 TANC1	3.77e-05	188	89	5	186fe1ea328c942910190a4240262c0d8642ea3b
ToppCell	IPF-Lymphoid-T_Regulatory\|Lymphoid / Disease state, Lineage and Cell class	EPHX2 TET2 MYOF ZEB1 HIVEP1	3.87e-05	189	89	5	7a260485c2a7c743c14d048e5e480ae0a9b8e32c
ToppCell	COPD-Lymphoid-T_Regulatory\|Lymphoid / Disease state, Lineage and Cell class	NCOA2 EPHX2 TET2 ZEB1 HIVEP1	4.07e-05	191	89	5	3ae18bc4e3dff49b5d5958da8ebc3f747274b69c
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	EPHX2 KLF12 ZEB1 PDE4D TNRC6A	4.07e-05	191	89	5	d9a6f61fcda4f5352488f7f55cb9b57aeacc717f
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	PDE4D HIVEP1 PHF3 TNRC6A MED13L	4.17e-05	192	89	5	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	PDE4D PTPRD TNRC6A AKAP13 MED13L	4.17e-05	192	89	5	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	SDK2 PDE4D NCAM2 TANC1 MAML3	4.17e-05	192	89	5	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	human_hepatoblastoma\|World / Sample and Cell Type and Tumor Cluster (all cells)	PDE4D HIVEP1 PHF3 TNRC6A MED13L	4.27e-05	193	89	5	e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCell	IPF-Endothelial\|IPF / Disease state, Lineage and Cell class	MMRN1 SHROOM4 ZEB1 TANC1 ARHGEF15	4.38e-05	194	89	5	9591993aa2dcba3d09a0f1ea8b8f2439c26482d6
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 PDE4D PTPRD MED13L MAML3	4.60e-05	196	89	5	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	Control-Control-Lymphocyte-T/NK-NK_activated\|Control / Disease, condition lineage and cell class	FAM156A SEC16A CARD11 N4BP1 TANC1	4.83e-05	198	89	5	76d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7
ToppCell	COVID-19_Mild\|World / Disease condition and Cell class	TET2 KMT2C BRD2 AKAP13 MED13L	4.83e-05	198	89	5	61ceb2245b6cb58e308b999a61d218c89dbc615e
ToppCell	lymphoid-NK_cell-NK_cell\|NK_cell / Lineage, cell class and subclass	PDE4D BAZ2A NR4A2 CNOT2 PYHIN1	4.94e-05	199	89	5	945fbf5845403a8b22d04963f50ad69c414b6153
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW09-Neuronal\|GW09 / Sample Type, Dataset, Time_group, and Cell type.	MAPRE3 PTPRD SRRM4 KLC2 PLPPR2	5.06e-05	200	89	5	e9eb348a66011d8aace4331f84690ae27cb0d061
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW23-OPC_related\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	SLITRK2 ZEB1 GTSE1 TNK2 TANC1	5.06e-05	200	89	5	439265194cb08d1373296bf8684cc31294cecb20
ToppCell	mild\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TET2 KMT2C PHF3 AKAP13 MED13L	5.06e-05	200	89	5	12f1685ce8f218433068e090c9d839cd5a1910bf
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW09-Neuronal-Neurons\|GW09 / Sample Type, Dataset, Time_group, and Cell type.	MAPRE3 PTPRD SRRM4 KLC2 PLPPR2	5.06e-05	200	89	5	ddac952ad1d46021c2d17d816de9bc31730a0941
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TOM1L1 TACC2 TANC1 ITPRID1 MAML3	5.06e-05	200	89	5	0eb9ad8c0373bcc62029ec21c590ed03aaacd039
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW23-OPC_related-OPC\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	SLITRK2 ZEB1 GTSE1 TNK2 TANC1	5.06e-05	200	89	5	0450a79c5fae5ccacdb990ae674e4734ef0c3691
ToppCell	PND01-03-samps-Mesenchymal-Matrix_fibroblast-matrix_-_mature_3\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	MMRN1 SYNPO2 TNK2 TACC2	1.64e-04	137	89	4	9bfdbc102cdd861996b3c4eac35b606be8af97eb
ToppCell	CTRL-Lymphoid-pDC\|CTRL / Disease state, Lineage and Cell class	MMRN1 SDK2 ZEB1 CARD11	1.74e-04	139	89	4	bbc10812b0c5b8c85e78171c12316becde8895c3
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L6b\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	MMRN1 SYNPO2 SDK2 NR4A2	1.79e-04	140	89	4	17005ca714ba03d7528fe7979ffb4654a46b666c
ToppCell	10x_3'_v3-blood_(10x_3'_v3)-myeloid-myeloid_dendritic-plasmacytoid_dendritic_cell\|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CRACD SDK2 PTPRD NCAM2	1.89e-04	142	89	4	7fa6b0f493634d25d68b4365b8c82cd43f5d31db
ToppCell	RV-16._Neuronal\|World / Chamber and Cluster_Paper	SHISA9 SLITRK2 NCAM2 DEPDC7	2.27e-04	149	89	4	3a2f8c4173dcf9e3f8d3b8ffddbc597098adf7a9
ToppCell	Pericytes-IPF_04\|World / lung cells shred on cell class, cell subclass, sample id	SYNPO2 ZEB1 PTPRD TANC1	2.33e-04	150	89	4	dbc202bd6db4fb5c8b2abd1200e074a2a9e63a59
ToppCell	Int-URO-Lymphocyte-T_NK-CD4_CTL\|Int-URO / Disease, Lineage and Cell Type	ZNF34 SYNPO2 FAM171B PYHIN1	2.51e-04	153	89	4	fdc7dfa8f4db90bfdc7180bf178cf6d2dd064d97
ToppCell	RV-16._Neuronal\|RV / Chamber and Cluster_Paper	SHISA9 SLITRK2 NCAM2 DEPDC7	2.51e-04	153	89	4	bed8bbf5c5cbfbf46a816066da472c3fdddecb5d
ToppCell	Children_(3_yrs)-Immune-dendritic_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	CRACD ZEB1 CARD11 WDFY4	3.04e-04	161	89	4	cd41abb7ae659d3d314281783a0aaad562b26037
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Astrocytoma\|TCGA-Brain / Sample_Type by Project: Shred V9	ZNF438 AKAP13 CARD11 WDFY4	3.12e-04	162	89	4	810881210e015c788814e4fe8d7a24c929cf2621
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c09-SLC4A10\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	PDE4D CXXC4 FAM171B PYHIN1	3.12e-04	162	89	4	3b89c3758835b7b9f9d4fb0bc8ed06da382fe48b
ToppCell	LV-16._Neuronal\|World / Chamber and Cluster_Paper	SHISA9 SLITRK2 NCAM2 DEPDC7	3.34e-04	165	89	4	6ed52cb756d21addf46c7f6c457458b01339fe04
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5\|TCGA-Ovary / Sample_Type by Project: Shred V9	FAM186B MAML3 TRAK1 ANKS1A	3.42e-04	166	89	4	32d2eaf8a5d03881bf74d680825af2d5110b082d
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLF12 ZEB1 PDE4D PYHIN1	3.50e-04	167	89	4	83969c36ac44b96afc9aa09400a99fa2b487f7ff
ToppCell	droplet-Heart-nan-24m-Hematologic-coronary_vascular_endothelial_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NDC1 SS18L1 MARK4 KLC2	3.50e-04	167	89	4	bad33497ceeab968a7eb8a48b921c6f936390743
ToppCell	BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c07-TYROBP\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	KLF12 PDE4D CARD11 PYHIN1	3.50e-04	167	89	4	ded4d6cccd3660662f12cf5a512de31d26325f1b
ToppCell	Adult-Mesenchymal-myofibroblast_cell\|Adult / Lineage, Cell type, age group and donor	CRACD SYNPO2 SDK2 ZEB1	3.50e-04	167	89	4	d584a8548a5317bd9686b3be8246ae6ed568796b
ToppCell	LA-16._Neuronal\|World / Chamber and Cluster_Paper	SHISA9 SLITRK2 NCAM2 DEPDC7	3.58e-04	168	89	4	2fd1fd2a16ac1c5eb028f93cc3a2477c7747693e
ToppCell	BAL-Severe-Myeloid-cDC-cDC-cDC_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	FAM171B DEPDC7 WDFY4 MAML3	3.58e-04	168	89	4	d60f7cd8269f373827f49c7785002cb38e4570a9
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Glomerular_Capillary_Endothelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB1 TANC1 ARHGEF15 ANKS1A	3.66e-04	169	89	4	987ff79ad563825dd9877ea8ccb536758f8c6700
ToppCell	BAL-Severe-Myeloid-cDC-cDC-cDC_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FAM171B DEPDC7 WDFY4 MAML3	3.66e-04	169	89	4	ccd98f9005aa0a88bd49f153be4e7200cc3dd0ac
ToppCell	PND07-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP2-CAP2_prolif\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	POLH TANC1 FAM171B ARHGEF15	3.66e-04	169	89	4	8a6d05b5d60b2b2e43a8ff7521feb79cd6dbd940
ToppCell	LV-16._Neuronal\|LV / Chamber and Cluster_Paper	SHISA9 SLITRK2 NCAM2 DEPDC7	3.66e-04	169	89	4	a8fc8ab0f0757e939e213efb61c03cfe390bf7d2
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SYNPO2 SDK2 NR4A2 KCNH5	3.74e-04	170	89	4	417b77c12a7982b1ce4b4bc57f30335d261220f5
ToppCell	droplet-Mammary_Gland-nan-3m-Endothelial-nan\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MMRN1 EPHX2 MARK4 TANC1	4.00e-04	173	89	4	fbc8ed566ea36c39c258dd6b3823c82f5d6eb17f
ToppCell	ASK452-Immune-B_cell\|ASK452 / Donor, Lineage and Cell class of Lung cells from Dropseq	SS18L1 GPATCH2 MAML1 CARD11	4.08e-04	174	89	4	69723f5666abc3af5f0431901a60246c9915ef81
ToppCell	LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.08e-04	174	89	4	61aa89b56ebda0eba1ba675d5f036992967f670f
ToppCell	PND07-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC-VEC_G2M\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	POLH TTLL4 CXXC4 DEPDC7	4.08e-04	174	89	4	6c36d607c48267a75ab4da6fb2fe3f931d1b3b52
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	MYOF SDK2 NR4A2 PWWP3B	4.08e-04	174	89	4	7d4b860e05b5931f6f9d757a68f75ff35597a47a
ToppCell	nucseq-Immune-Immune_Myeloid-Myeloid_Dendritic-pDC\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SDK2 HIVEP1 CARD11 WDFY4	4.17e-04	175	89	4	37c2d4e0b6e9a3171931797ce9a54f3347288e57
ToppCell	LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.17e-04	175	89	4	98cb577df466700e72d1bbc6689205ccf2e7fcba
ToppCell	droplet-Liver-LIVER-30m-Endothelial\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHISA9 ZEB1 GTSE1 ARHGEF15	4.26e-04	176	89	4	4d2fb51e71bed0d72f3d7f89d395744860885a5f
ToppCell	droplet-Liver-LIVER-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHISA9 ZEB1 GTSE1 ARHGEF15	4.26e-04	176	89	4	4880fa20b50eb10358e08567e08559ef2954f237
ToppCell	droplet-Limb_Muscle-Pre-Sort-18m-Lymphocytic-nan\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PDE4D SS18L1 MARK4 CARD11	4.26e-04	176	89	4	096cbcefd9dcbaee660568998ba210253b58501e
ToppCell	LPS-antiTNF-Lymphocytic_NKT-T_cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.26e-04	176	89	4	ea27e18407b8a13e8212830da859efeb8f158690
ToppCell	droplet-Liver-LIVER-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHISA9 ZEB1 GTSE1 ARHGEF15	4.26e-04	176	89	4	fcdddd949ca05b3ecde240db9e38296a6eab2d6a
ToppCell	LPS-antiTNF-Lymphocytic_NKT-T_cells-T-cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.26e-04	176	89	4	bfbab3c5b738b3b0b1540f2059d0245fbd8c0031
ToppCell	droplet-Limb_Muscle-Pre-Sort-18m-Lymphocytic\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PDE4D SS18L1 MARK4 CARD11	4.26e-04	176	89	4	90198fb79e8b08e9e7df538cbc05ad7141e78517
ToppCell	COVID-19-lung-B_cells\|lung / Disease (COVID-19 only), tissue and cell type	NCOA3 CARD11 WDFY4 TRIM64C	4.36e-04	177	89	4	f54691e5558091c1734ab15153a10bff15ed171e
ToppCell	CTRL-Lymphoid-T_cell_&_NK_cell\|CTRL / Disease state, Lineage and Cell class	KLF12 ZEB1 CARD11 PYHIN1	4.36e-04	177	89	4	e73d8e78a96b63e27a8a7694c62b3c44ec7ecfe6
ToppCell	LPS_only-Lymphocytic_NKT-iNKT/MAIT\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.54e-04	179	89	4	de3ddc1264e43727be50d69b81cc84a3c91812a2
ToppCell	LPS_only-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.54e-04	179	89	4	def981e97e3ff9019910c9af3861ca0d08eb0d0f
ToppCell	LPS-antiTNF-Lymphocytic_NKT\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KLF12 NR4A2 CARD11 PYHIN1	4.54e-04	179	89	4	ecea75c568911ff56939c9f67ab901497bd4356c
ToppCell	CTRL-Lymphoid-B_cell\|CTRL / Disease state, Lineage and Cell class	KLF12 ZEB1 PDE4D CARD11	4.54e-04	179	89	4	dd4055c0a8360ea10323ef6249519a6ae08fc05a
ToppCell	COPD-Myeloid-pDC\|Myeloid / Disease state, Lineage and Cell class	SDK2 ZEB1 HIVEP1 CARD11	4.54e-04	179	89	4	29b058c5e33fda9f0d738c074bdb67ff16b9b6d5
ToppCell	IPF-Myeloid-pDC\|Myeloid / Disease state, Lineage and Cell class	SDK2 ZEB1 HIVEP1 CARD11	4.64e-04	180	89	4	0f8567aa835d4e3a52f6631ae15216eca18a030c
ToppCell	Control-Endothelial_cells-Capillary_endothelial_cells\|Control / group, cell type (main and fine annotations)	SHROOM4 ZEB1 ITPRID1 SHROOM2	4.64e-04	180	89	4	b043f9ffb9a4cd427a15bebb86a711c7b08866e8
ToppCell	critical-Lymphoid-NK\|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	SLITRK2 KIAA1549L NCAM2 ARHGEF15	4.64e-04	180	89	4	5abf778395392244daaec876f306ed7e4f388686
ToppCell	Severe-Lymphoid-pDC\|Severe / Condition, Lineage, Cell class and cell subclass	MMRN1 SDK2 CARD11 WDFY4	4.74e-04	181	89	4	2caecb7c5dcdad46fd02b4ffb73cb613ce835187
ToppCell	COVID-19-T_cells-Tregs\|COVID-19 / group, cell type (main and fine annotations)	KLF12 ZEB1 CARD11 PYHIN1	4.74e-04	181	89	4	534659cf754326c6a73c0daa30e9d610612a0292
ToppCell	Severe-Lymphoid-pDC-\|Severe / Condition, Lineage, Cell class and cell subclass	MMRN1 SDK2 CARD11 WDFY4	4.74e-04	181	89	4	277ce4c49121da0990a5933b19d2c6af9bbe253e
ToppCell	E18.5-samps-Endothelial-Mature_fetal_endothelial-endothelial_cells_A\|E18.5-samps / Age Group, Lineage, Cell class and subclass	MMRN1 ZEB1 GTSE1 ARHGEF15	4.84e-04	182	89	4	ea4f6c8f600ffe9f8e0609637b3371a5ac48ca03
ToppCell	PCW_05-06-Neuronal-Neuronal_SCP-neuro_proliferating_SCP2_(1)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	SHISA9 SLITRK2 GTSE1 NR4A2	4.84e-04	182	89	4	f7f9be9c7ef8da9864d6aefe20043b26e1bb8697
ToppCell	IPF-Lymphoid-B\|IPF / Disease state, Lineage and Cell class	NCOA3 ZEB1 CARD11 WDFY4	4.94e-04	183	89	4	e37d2c015c34471a8a54a0299e94b0371e1ada5a
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CRACD PTPRD TANC1 MAML3	4.94e-04	183	89	4	3c516fe5083f02bad1f464ed284010b4131a833c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CRACD PTPRD TANC1 MAML3	4.94e-04	183	89	4	9c2689d76fc6d30f5ab093428aa669d0a98953cf
ToppCell	PCW_05-06-Neuronal-Neuronal_SCP-neuro_SCP_(0)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	SHISA9 SLITRK2 SRRM4 NR4A2	4.94e-04	183	89	4	f517215ff45dec914af52dfdbc4579c19654c3aa
ToppCell	Endothelial-A-IPF_02\|World / lung cells shred on cell class, cell subclass, sample id	MMRN1 MAPRE3 ZEB1 ARHGEF15	4.94e-04	183	89	4	2c3f2c25c38f0598b4787d2ec335efe00fdc9751
ToppCell	NS-critical-d_0-4-Lymphoid-Treg\|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	KLF12 PDE4D HP1BP3 PYHIN1	4.94e-04	183	89	4	f478dfa231fc1b12ead0183cc9d22077cdf43d1f
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLITRK2 PTPRD SRRM4 NCAM2	5.04e-04	184	89	4	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	nucseq-Immune-Lymphocytic_B\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NCOA3 ZEB1 CARD11 WDFY4	5.04e-04	184	89	4	911658e7bb499c1bbc8419eec8ff88729bc39a75
ToppCell	Control-Lymphoid-B\|Control / Disease state, Lineage and Cell class	NCOA3 KLF12 ZEB1 CARD11	5.04e-04	184	89	4	de0294f879268bfd68e91adcc2adba211d221b7a
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive\|renal_medulla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	SYNPO2 HIVEP1 PTPRD AKAP13	5.04e-04	184	89	4	d2bf0135eb56bb410997dccea39c5ede88a0617f
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	NCOA2 HIVEP1 TTLL4 AKAP13 MED13L SHROOM2 CREBBP ANKS1A	2.89e-07	174	85	8	7530_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	ZEB1 MARK3 PHF3 TACC2 N4BP1 CREBBP CNOT2 ANKS1A	3.74e-07	180	85	8	4541_DN
Drug	Ivermectin [70288-86-7]; Down 200; 4.6uM; PC3; HT_HG-U133A	NCOA2 TRAF3IP2 PDE4D KIAA1549L AKAP13 SHROOM2 PLPPR2 TRAK1	8.31e-07	200	85	8	5853_DN
Drug	irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A	NCOA2 NCOA3 ZEB1 AKAP13 TACC2 MED13L ANKS1A	3.60e-06	171	85	7	7535_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	NCOA2 NCOA3 AKAP13 MED13L TRRAP CREBBP ANKS1A	5.62e-06	183	85	7	7498_DN
Drug	Lovastatin [75330-75-5]; Up 200; 9.8uM; MCF7; HT_HG-U133A	TRAF3IP2 BAZ2A MARK4 NR4A2 N4BP1 TRAK1 PYHIN1	6.71e-06	188	85	7	2854_UP
Drug	Fusaric acid [536-69-6]; Up 200; 22.4uM; MCF7; HT_HG-U133A	ZNF34 PDE4D BAZ2A PHF3 TTLL4 MARK4 NR4A2	8.24e-06	194	85	7	3245_UP
Drug	Nifedipine [21829-25-4]; Down 200; 11.6uM; PC3; HT_HG-U133A	NCOA3 BAZ2A POLH GTSE1 MARK4 AKAP13 TRAK1	8.24e-06	194	85	7	1814_DN
Drug	Atractyloside potassium salt [102130-43-8]; Down 200; 5uM; PC3; HT_HG-U133A	ZNF34 MYOF KLF12 POLH NR4A2 EYA3 TRAK1	8.52e-06	195	85	7	7393_DN
Drug	Aceclofenac [89796-99-6]; Up 200; 11.2uM; PC3; HT_HG-U133A	NCOA3 NCOR2 HIVEP1 MARK4 NR4A2 AKAP13 SHROOM2	8.81e-06	196	85	7	7269_UP
Drug	sodium 4-phenylbutyrate; Up 200; 100uM; HL60; HG-U133A	KLF12 TP63 MAML1 MED13L SS18 PLPPR2 HP1BP3	8.81e-06	196	85	7	363_UP
Drug	Ofloxacin [82419-36-1]; Down 200; 11uM; PC3; HT_HG-U133A	EPHX2 TRAF3IP2 NCOA3 NCOR2 MARK4 NR4A2 SS18	8.81e-06	196	85	7	3673_DN
Drug	(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Down 200; 12.2uM; PC3; HT_HG-U133A	NCOA3 PHF3 MARK4 NR4A2 AKAP13 N4BP1 EYA3	9.11e-06	197	85	7	5108_DN
Drug	Trichlorfon [52-68-6]; Down 200; 15.6uM; PC3; HT_HG-U133A	NCOA3 PHF3 POLH MARK4 TNK2 MAP3K7 SS18	9.41e-06	198	85	7	1797_DN
Drug	Naftopidil dihydrochloride [57149-08-3]; Up 200; 8.6uM; MCF7; HT_HG-U133A	MAPRE3 MYOF ZEB1 PHF3 N4BP1 EYA3 PLPPR2	9.41e-06	198	85	7	7331_UP
Drug	Sulfasalazine [599-79-1]; Down 200; 10uM; HL60; HG-U133A	MYOF ZEB1 GPATCH2 AKAP13 N4BP1 MAP3K7 ARHGEF15	9.73e-06	199	85	7	1733_DN
Drug	Trimethylcolchicinic acid [3482-37-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A	BAZ2A PHF3 TTLL4 NR4A2 TNK2 N4BP1 TRRAP	9.73e-06	199	85	7	2802_DN
Drug	Dihydroergotamine tartrate [5989-77-5]; Up 200; 3uM; HL60; HG-U133A	TRAF3IP2 NCOA3 PDE4D NR4A2 GPATCH2 AKAP13	3.86e-05	167	85	6	1398_UP
Drug	AC1LA6KT	NCOA3 NCOR2 SYNPO2 MAML1	3.95e-05	51	85	4	CID000508110
Drug	Nocodazole [31430-18-9]; Up 200; 13.2uM; HL60; HG-U133A	NCOA3 PDE4D HIVEP1 MARK4 NR4A2 MED13L	5.17e-05	176	85	6	1393_UP
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	NCOA2 TRAF3IP2 MYOF HIVEP1 MED13L CREBBP	5.33e-05	177	85	6	6434_DN
Drug	Pyrvinium pamoate [3546-41-6]; Up 200; 3.4uM; PC3; HT_HG-U133A	TRAF3IP2 ZNF34 KLF12 PDE4D NR4A2 NCAM2	6.42e-05	183	85	6	6339_UP
Drug	afimoxifene	NCOA2 BCL9L MYOF ZEB1 BRD2 TP63 MARK4 PWWP3B SHROOM2	7.49e-05	479	85	9	ctd:C016601
Drug	2-propylpentanoic acid; Up 200; 1000uM; SKMEL5; HG-U133A	NCOA3 MARK4 NR4A2 TNK2 N4BP1 MAP3K7	8.37e-05	192	85	6	629_UP
Drug	Sulfamethoxazole [723-46-6]; Down 200; 15.8uM; MCF7; HT_HG-U133A	TRAF3IP2 MYOF ZEB1 POLH AKAP13 TRAK1	8.61e-05	193	85	6	4690_DN
Drug	Carbarsone [121-59-5]; Up 200; 15.4uM; MCF7; HT_HG-U133A	NCOA2 MYOF ZEB1 PHF3 NR4A2 HP1BP3	8.61e-05	193	85	6	3250_UP
Drug	Folinic acid calcium salt [6035-45-6]; Up 200; 7.8uM; MCF7; HT_HG-U133A	NCOA2 EPHX2 BAZ2A PHF3 MAML1 SS18	8.61e-05	193	85	6	4725_UP
Drug	wortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A	EPHX2 KLF12 TP63 NR4A2 TRAK1 PYHIN1	8.61e-05	193	85	6	5603_UP
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A	NCOA2 PHF3 GTSE1 AKAP13 MED13L PLPPR2	8.86e-05	194	85	6	4361_DN
Drug	Cisapride [81098-60-4]; Down 200; 8.6uM; PC3; HT_HG-U133A	TRAF3IP2 MAPRE3 ZEB1 PDE4D MAP3K7 SS18	9.11e-05	195	85	6	6706_DN
Drug	Thiamphenicol [15318-45-3]; Up 200; 11.2uM; MCF7; HT_HG-U133A	TP63 POLH MARK4 NR4A2 PLPPR2 TRAK1	9.11e-05	195	85	6	7033_UP
Drug	ICI182,780; Up 200; 1uM; PC3; HT_HG-U133A	NCOA2 ZNF34 PHF3 GTSE1 TNK2 MED13L	9.11e-05	195	85	6	6918_UP
Drug	Rapamycin; Up 200; 0.1uM; HL60; HT_HG-U133A	MAPRE3 MYOF KLF12 KIAA1549L PHF3 TNK2	9.11e-05	195	85	6	2702_UP
Drug	Fendiline hydrochloride [13636-18-5]; Up 200; 11.4uM; HL60; HG-U133A	TRAF3IP2 NCOA3 MYOF BAZ2A AKAP13 MAML3	9.11e-05	195	85	6	1573_UP
Drug	Praziquantel [55268-74-1]; Down 200; 12.8uM; MCF7; HT_HG-U133A	MYOF BAZ2A PHF3 POLH KLC2 TRAK1	9.37e-05	196	85	6	7228_DN
Drug	clozapine; Up 200; 10uM; MCF7; HT_HG-U133A	MYOF PHF3 NR4A2 KLC2 TRAK1 PYHIN1	9.37e-05	196	85	6	5226_UP
Drug	Zidovudine, AZT [30516-87-1]; Down 200; 15uM; MCF7; HT_HG-U133A	ZNF34 NR4A2 AKAP13 N4BP1 SS18 TRAK1	9.64e-05	197	85	6	3211_DN
Drug	Diazoxide [364-98-7]; Down 200; 17.4uM; PC3; HT_HG-U133A	TRAF3IP2 MARK4 TNK2 TACC2 N4BP1 PLPPR2	9.64e-05	197	85	6	5810_DN
Drug	Cloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; PC3; HT_HG-U133A	TRAF3IP2 KLF12 ZEB1 MARK4 SS18 TRAK1	9.64e-05	197	85	6	2126_DN
Drug	Doxazosin mesylate [77883-43-3]; Down 200; 7.4uM; MCF7; HT_HG-U133A	NCOA2 TRAF3IP2 MYOF BAZ2A AKAP13 PLPPR2	9.64e-05	197	85	6	4988_DN
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; MCF7; HT_HG-U133A	MYOF BAZ2A CXXC4 NR4A2 TNK2 HP1BP3	9.64e-05	197	85	6	4832_DN
Drug	Lovastatin [75330-75-5]; Down 200; 9.8uM; PC3; HT_HG-U133A	MAPRE3 NCOR2 BAZ2A GPATCH2 SS18 TRAK1	9.64e-05	197	85	6	6633_DN
Drug	Atropine sulfate monohydrate [5908-99-6]; Down 200; 5.8uM; PC3; HT_HG-U133A	ZNF34 KLF12 BAZ2A MARK4 NR4A2 SS18	9.64e-05	197	85	6	5865_DN
Drug	Hydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A	MAPRE3 TTLL4 MARK4 NR4A2 MAML1 PLPPR2	9.64e-05	197	85	6	6011_UP
Drug	Methyldopa (L,-) [555-30-6]; Up 200; 19uM; MCF7; HT_HG-U133A	MAPRE3 ZEB1 PTPRD TP63 EYA3 ARHGEF15	9.64e-05	197	85	6	3234_UP
Drug	nocodazole; Down 200; 1uM; MCF7; HG-U133A	BAZ2A MARK4 TACC2 SHROOM2 MAP3K7 CNOT2	9.91e-05	198	85	6	621_DN
Drug	Nalidixic acid sodium salt hydrate; Down 200; 14.6uM; MCF7; HT_HG-U133A	EPHX2 MYOF MARK4 NR4A2 SS18 HP1BP3	9.91e-05	198	85	6	2297_DN
Drug	Minoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A	MAP7D1 BAZ2A PHF3 POLH MARK4 HP1BP3	9.91e-05	198	85	6	4800_DN
Drug	Tyloxapol [25301-02-4]; Down 200; 4uM; MCF7; HT_HG-U133A	NCOA2 BAZ2A PHF3 CXXC4 NR4A2 PLPPR2	9.91e-05	198	85	6	6452_DN
Drug	estradiol, USP; Up 200; 0.01uM; HL60; HT_HG-U133A	NCOR2 BAZ2A TP63 NR4A2 TNK2 EYA3	9.91e-05	198	85	6	6200_UP
Drug	Phentolamine hydrochloride [73-05-2]; Down 200; 12.6uM; HL60; HT_HG-U133A	BAZ2A PHF3 TTLL4 MAML1 N4BP1 ANKS1A	9.91e-05	198	85	6	2362_DN
Drug	Bisoprolol fumarate; Down 200; 9uM; HL60; HT_HG-U133A	MYOF BAZ2A MARK3 TTLL4 NR4A2 ANKS1A	9.91e-05	198	85	6	1287_DN
Drug	Sulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; HL60; HT_HG-U133A	PHF3 MARK4 NR4A2 AKAP13 N4BP1 PLPPR2	1.02e-04	199	85	6	2550_DN
Drug	Acenocoumarol [152-72-7]; Down 200; 11.4uM; PC3; HT_HG-U133A	NCOA3 MYOF ZEB1 BAZ2A PHF3 MED13L	1.02e-04	199	85	6	2077_DN
Drug	Ergocryptine-alpha [511-09-1]; Down 200; 7uM; PC3; HT_HG-U133A	EPHX2 TRAF3IP2 POLH AKAP13 N4BP1 TRAK1	1.02e-04	199	85	6	4552_DN
Drug	Propylthiouracil [51-52-5]; Down 200; 23.4uM; PC3; HT_HG-U133A	MAPRE3 NCOR2 PHF3 N4BP1 EYA3 TRAK1	1.05e-04	200	85	6	4076_DN
Drug	Procaine hydrochloride [51-05-8]; Up 200; 14.6uM; PC3; HT_HG-U133A	NCOA3 NCOR2 MYOF PHF3 KERA SS18	1.05e-04	200	85	6	6329_UP
Drug	MF101 extract	NCOA2 CREBBP	1.37e-04	5	85	2	ctd:C517398
Drug	butamben	NCOA2 NCOA3	2.05e-04	6	85	2	ctd:C004605
Drug	Chelidonine monohydrate (+) [476-32-4]; Up 200; 10.8uM; HL60; HG-U133A	NCOA3 PDE4D NR4A2 AKAP13 HP1BP3	2.90e-04	155	85	5	1786_UP
Drug	1,1,1-trichloroethane	NCOA2 MAPRE3 POLH TRRAP CREBBP	2.99e-04	156	85	5	CID000006278
Drug	imiprothrin	NCOA2 BRD2	3.80e-04	8	85	2	CID000123622
Drug	Pergolide mesylate [66104-23-2]; Up 200; 9.8uM; HL60; HT_HG-U133A	TRAF3IP2 PDE4D NR4A2 AKAP13 SS18	3.97e-04	166	85	5	2403_UP
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA	NCOA2 TRAF3IP2 TACC2 MED13L CREBBP	4.68e-04	172	85	5	1072_DN
Drug	Vigabatrin [60643-86-9]; Up 200; 31uM; HL60; HT_HG-U133A	TRAF3IP2 BAZ2A NR4A2 AKAP13 CREBBP	4.93e-04	174	85	5	2452_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 TRAF3IP2 TACC2 CREBBP CNOT2	5.33e-04	177	85	5	5308_DN
Drug	Metaproterenol sulfate, orciprenaline sulfate [5874-97-5]; Up 200; 7.6uM; PC3; HT_HG-U133A	NCOA3 PDE4D MARK4 MAML1 TACC2	5.61e-04	179	85	5	4248_UP
Drug	thioridazine hydrochloride; Up 200; 10uM; HL60; HT_HG-U133A	NCOA2 NCOA3 MYOF PDE4D CXXC4	5.75e-04	180	85	5	1171_UP
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; PC3; HT_HG-U133A	NCOA2 NCOA3 GTSE1 TACC2 CNOT2	5.89e-04	181	85	5	1791_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	NCOA2 TACC2 MED13L CREBBP CNOT2	6.04e-04	182	85	5	3887_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HG-U133A	NCOA2 GTSE1 TACC2 MED13L CREBBP	6.04e-04	182	85	5	1951_DN
Drug	Fenoterol hydrobromide [1944-12-3]; Up 200; 10.4uM; PC3; HT_HG-U133A	PDE4D BAZ2A NR4A2 TACC2 N4BP1	6.04e-04	182	85	5	6331_UP
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	NCOA2 PHF3 N4BP1 CREBBP CNOT2	6.35e-04	184	85	5	2321_DN
Drug	cyclopropyl	NCOA2 EPHX2 TP63	6.36e-04	45	85	3	CID000123162
Drug	Androstenedione	NCOA2 NCOA3 CREBBP	6.36e-04	45	85	3	ctd:D000735
Drug	Methamphetamine	BCL9L NCOR2 PDE4D BRD2 BAZ2A TTLL4 TNRC6A NR4A2 AKAP13 TACC2 N4BP1 MAP3K7 PLPPR2 ARHGEF15	6.50e-04	1401	85	14	ctd:D008694
Drug	retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA	TRAF3IP2 MAP7D1 BAZ2A PHF3 N4BP1	6.51e-04	185	85	5	1049_DN
Drug	Terbutaline hemisulfate [23031-32-5]; Up 200; 7.2uM; HL60; HG-U133A	NCOA3 PHF3 NR4A2 AKAP13 PLPPR2	6.51e-04	185	85	5	1585_UP
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	EPHX2 NR4A2 TNK2 SS18 TRAK1	6.83e-04	187	85	5	5204_UP
Drug	17-AAG; Up 200; 1uM; PC3; HT_HG-U133A	ZEB1 PDE4D N4BP1 EYA3 CREBBP	6.83e-04	187	85	5	5958_UP
Drug	Clioquinol [130-26-7]; Up 200; 13uM; MCF7; HT_HG-U133A	KLF12 ZEB1 PTPRD TP63 EYA3	6.83e-04	187	85	5	5258_UP
Drug	Thonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A	ZNF34 MAPRE3 NCOR2 PHF3 NR4A2	6.83e-04	187	85	5	5678_UP
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; HL60; HG-U133A	TRAF3IP2 HIVEP1 GTSE1 N4BP1 ARHGEF15	7.17e-04	189	85	5	2041_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	MYOF HIVEP1 MAML1 PLPPR2 TRAK1	7.17e-04	189	85	5	5578_DN
Drug	resveratrol; Down 200; 50uM; MCF7; HG-U133A	NCOA3 MAP7D1 GTSE1 TRRAP PPID	7.34e-04	190	85	5	622_DN
Drug	radicicol, diheterospora chlamydosporia; Up 200; 0.1uM; MCF7; HT_HG-U133A	ZEB1 PHF3 NR4A2 PPID TRAK1	7.34e-04	190	85	5	5579_UP
Drug	Muramic acid, N-acetyl [10597-89-4]; Down 200; 13.6uM; PC3; HT_HG-U133A	MARK4 KLC2 SS18 HP1BP3 TRAK1	7.34e-04	190	85	5	4582_DN
Drug	2-propylpentanoic acid; Up 200; 10000uM; HL60; HG-U133A	NCOA3 MARK4 KLC2 N4BP1 PLPPR2	7.34e-04	190	85	5	410_UP
Drug	Azacytidine-5 [320-67-2]; Down 200; 16.4uM; PC3; HT_HG-U133A	TRAF3IP2 BAZ2A PHF3 TTLL4 SS18	7.34e-04	190	85	5	4010_DN
Drug	Nocodazole [31430-18-9]; Down 200; 13.2uM; PC3; HT_HG-U133A	NCOA3 KIAA1549L TACC2 SS18 TRAK1	7.34e-04	190	85	5	7145_DN
Drug	Thioguanosine [85-31-4]; Up 200; 12.6uM; MCF7; HT_HG-U133A	EPHX2 MAPRE3 MYOF MAML1 KERA	7.34e-04	190	85	5	2619_UP
Drug	2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	NCOA2 NCOA3	7.41e-04	11	85	2	ctd:C061137
Drug	Metergoline [17692-51-2]; Up 200; 10uM; MCF7; HT_HG-U133A	BAZ2A N4BP1 MED13L PLPPR2 TRAK1	7.51e-04	191	85	5	5344_UP
Drug	Beta-Escin [11072-93-8]; Down 200; 3.2uM; MCF7; HT_HG-U133A	EPHX2 MYOF MAML1 N4BP1 TRAK1	7.51e-04	191	85	5	3890_DN
Drug	Monobenzone [103-16-2]; Down 200; 20uM; PC3; HT_HG-U133A	ZEB1 GTSE1 TRRAP SS18 HP1BP3	7.69e-04	192	85	5	6713_DN
Drug	Furosemide [54-31-9]; Up 200; 12uM; HL60; HG-U133A	PHF3 SS18L1 NR4A2 N4BP1 MAP3K7	7.69e-04	192	85	5	1580_UP
Drug	Tiapride hydrochloride [51012-33-0]; Down 200; 11uM; MCF7; HT_HG-U133A	PHF3 MARK4 N4BP1 SS18 HP1BP3	7.69e-04	192	85	5	2292_DN
Drug	0317956-0000 [391210-11-0]; Down 200; 1uM; PC3; HT_HG-U133A	NCOA2 NCOR2 ZEB1 SS18 HP1BP3	7.69e-04	192	85	5	4334_DN
Drug	Benfotiamine [22457-89-2]; Down 200; 8.6uM; HL60; HT_HG-U133A	ZEB1 PHF3 NR4A2 AKAP13 SS18	7.87e-04	193	85	5	2177_DN
Drug	Tiaprofenic acid [33005-95-7]; Up 200; 15.4uM; MCF7; HT_HG-U133A	NCOA2 MYOF NR4A2 N4BP1 TRAK1	7.87e-04	193	85	5	2852_UP
Disease	Sezary Syndrome	TET2 KMT2C ZEB1 CARD11 CREBBP	1.61e-08	27	88	5	C0036920
Disease	Prostatic Neoplasms	NCOA2 TET2 NCOA3 KMT2C PDE4D BAZ2A TOM1L1 AKAP13 MAP3K7 CREBBP PYHIN1	2.25e-06	616	88	11	C0033578
Disease	Malignant neoplasm of prostate	NCOA2 TET2 NCOA3 KMT2C PDE4D BAZ2A TOM1L1 AKAP13 MAP3K7 CREBBP PYHIN1	2.25e-06	616	88	11	C0376358
Disease	visual impairment and progressive phthisis bulbi (implicated_via_orthology)	MARK3 MARK4	5.26e-05	4	88	2	DOID:0070356 (implicated_via_orthology)
Disease	cognitive function measurement	SHISA9 ZNF438 NCOA2 SYNPO2 PDE4D HIVEP1 PTPRD TNRC6A NCAM2 MAP3K7 FAM186B SS18 MAML3	3.21e-04	1434	88	13	EFO_0008354
Disease	Gastric Adenocarcinoma	BRD2 TNK2 TRRAP	3.32e-04	45	88	3	C0278701
Disease	total blood protein measurement	ZNF438 NCOA2 NCOA3 NCOR2 TP63 MARK4 SEC16A	3.96e-04	449	88	7	EFO_0004536
Disease	ovarian carcinoma	CHMP4C SYNPO2 NCAM2 CARD11 TACC2 CNOT2	4.06e-04	321	88	6	EFO_0001075
Disease	AMYOTROPHIC LATERAL SCLEROSIS 1	SS18L1 XIAP CREBBP	4.54e-04	50	88	3	C1862939
Disease	response to bronchodilator, FEV/FEC ratio	NCOA2 TET2 MAPRE3 NCOR2 SDK2 PDE4D PTPRD KERA CARD11	4.69e-04	766	88	9	EFO_0004713, GO_0097366
Disease	cognitive decline measurement	PDE4D PTPRD CXXC4 NCAM2 MED13L MAP3K7 HP1BP3	6.34e-04	486	88	7	EFO_0007710
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	TET2 TRAF3IP2 HIVEP1 TNRC6A NCAM2 TACC2 MAP3K7 FAM186B MAML3	6.46e-04	801	88	9	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	body surface area	NCOR2 MAP7D1 HIVEP1 TNRC6A KERA AKAP13 MED13L SPATA31C1	6.77e-04	643	88	8	EFO_0022196
Disease	ovarian neoplasm	CHMP4C ZEB1 TP63 XIAP	7.06e-04	134	88	4	C0919267
Disease	Malignant neoplasm of ovary	CHMP4C ZEB1 TP63 XIAP	7.67e-04	137	88	4	C1140680
Disease	Arthritis, Psoriatic	TRAF3IP2 NR4A2	7.82e-04	14	88	2	C0003872
Disease	unipolar depression, mood disorder, response to antidepressant	NDC1 PTPRD	7.82e-04	14	88	2	EFO_0003761, EFO_0004247, GO_0036276
Disease	obesity	CRACD TOM1L1 CXXC4 NCAM2 CARD11	7.87e-04	241	88	5	EFO_0001073
Disease	myelodysplastic syndrome (implicated_via_orthology)	TET2 CREBBP	9.00e-04	15	88	2	DOID:0050908 (implicated_via_orthology)
Disease	squamous cell carcinoma	MARK3 TP63 SEC16A	1.07e-03	67	88	3	EFO_0000707
Disease	radiation-induced disorder	PTPRD SRRM4 MAP3K7	1.07e-03	67	88	3	EFO_0009565
Disease	prostate cancer (is_marker_for)	NCOA2 NCOA3 KMT2C XIAP	1.24e-03	156	88	4	DOID:10283 (is_marker_for)
Disease	response to antiviral drug	NCAM2 MAP3K7	1.30e-03	18	88	2	EFO_0010123
Disease	lymphocyte count	NCOA2 TET2 KLF12 PDE4D HIVEP1 BRD2 MARK3 MARK4 CARD11 MED13L PPID ARHGEF15	1.33e-03	1464	88	12	EFO_0004587
Disease	psoriasis	TRAF3IP2 TP63 AKAP13 ITPRID1 SPATA31C1	1.37e-03	273	88	5	EFO_0000676
Disease	neuroticism measurement, wellbeing measurement, depressive symptom measurement	SHISA9 MAML3	1.45e-03	19	88	2	EFO_0007006, EFO_0007660, EFO_0007869
Disease	non-small cell lung carcinoma	NCOA2 TP63 ANKS1A	1.48e-03	75	88	3	EFO_0003060
Disease	energy expenditure measurement	KLF12 GPATCH2	1.61e-03	20	88	2	EFO_0008005
Disease	unipolar depression, alcohol dependence	KLF12 NR4A2 MAP3K7	1.66e-03	78	88	3	EFO_0003761, MONDO_0007079
Disease	platelet component distribution width	NCOR2 BAZ2A MARK3 MARK4 AKAP13 DEPDC7 ARHGEF15 ANKS1A	1.88e-03	755	88	8	EFO_0007984
Disease	Granulomatous Slack Skin	ZEB1 CARD11	1.95e-03	22	88	2	C0376407
Disease	pulse pressure measurement, alcohol consumption measurement	TACC2 TRAK1	1.95e-03	22	88	2	EFO_0005763, EFO_0007878
Disease	hippocampal volume	TRAF3IP2 PTPRD AKAP13 MED13L ITPRID1	1.98e-03	297	88	5	EFO_0005035
Disease	QRS duration	SHISA9 KLF12 PTPRD MAP3K7 ANAPC7	2.01e-03	298	88	5	EFO_0005055
Disease	acute myeloid leukemia (is_implicated_in)	NCOA2 TET2 CREBBP	2.05e-03	84	88	3	DOID:9119 (is_implicated_in)
Disease	Lymphoma, T-Cell, Cutaneous	ZEB1 CARD11	2.14e-03	23	88	2	C0079773
Disease	uric acid measurement	TET2 MYOF NDC1 MARK4 GPATCH2 AKAP13 TANC1	2.33e-03	610	88	7	EFO_0004761
Disease	neutrophil percentage of leukocytes	TET2 MAPRE3 KLF12 HIVEP1 MARK3 MARK4 AKAP13	2.33e-03	610	88	7	EFO_0007990
Disease	FEV change measurement, response to zileuton	EPHX2 SDK2	2.52e-03	25	88	2	EFO_0005921, EFO_0007676
Disease	Ischemic stroke, coronary artery disease	BCL9L SRRM4 NCAM2	2.66e-03	92	88	3	EFO_0001645, HP_0002140
Disease	subcutaneous adipose tissue measurement	PTPRD EBLN1 KCNH5	2.74e-03	93	88	3	EFO_0004766
Disease	smoking cessation	EPHX2 MAPRE3 TNRC6A MAML3 ANKS1A	2.92e-03	325	88	5	EFO_0004319

Protein segments in the cluster

Peptide	Gene	Start	Entry
QPTPSPQQLASSKPM	BAZ2A	1346	Q9UIF9
PQQLASSKPMNRPSA	BAZ2A	1351	Q9UIF9
SSLPTVIMRNKPSQP	AKAP13	1856	Q12802
TMNTRNVPQQSLPSP	CREBBP	1871	Q92793
MSAQSLPAATPPTQK	ARHGEF15	1	O94989
PQPPLISSMDSISQK	ANKS1A	321	Q92625
MSPSTQQPALGKQRP	FAM186B	596	Q8IYM0
PKIPQPKRQSTMVNS	DEPDC7	231	Q96QD5
SSLPAQPNRKPGMSS	CHMP4C	191	Q96CF2
PMPQAALDPKANFST	TNK2	911	Q07912
RAQKQTPMASSPRPK	HP1BP3	146	Q5SSJ5
KPSVMAPAPAAQRLS	EYA3	241	Q99504
LLTMSNNNPELFSPP	ANAPC7	26	Q9UJX3
ADNPSPNLMPASAQA	MAML1	356	Q92585
NPLNASASLPAAMPI	NCOR2	2366	Q9Y618
MDPLQKRNPASPSKS	FAM156A	1	Q8NDB6
ENKESIPSLPQSPMR	KMT2C	4256	Q8NEZ4
PQMNTPVTLNSAAPA	MED13L	1016	Q71F56
DLSQRMTPPVANPNK	MAML3	611	Q96JK9
LQMPSLPNSQSPAEN	ITPRID1	436	Q6ZRS4
QKTMPSASVPPNKIQ	MMRN1	36	Q13201
SVPQASSPKSQMPLQ	KCNH5	946	Q8NCM2
APTQTFPRTPQEKMQ	FAM90A27P	116	A6NNH2
PSKRSPMCNQPSINK	PDE4D	251	Q08499
QLQPLAPCPNSKESM	MAP3K7	506	O43318
RKPQAMHTGLPNPTN	KIAA1549L	746	Q6ZVL6
NTPDMNKNVAKPSPV	GTSE1	676	Q9NYZ3
EPPNPRMKRASSLNF	KLC2	571	Q9H0B6
QAPTMDSPLEKNPRS	PLPPR2	306	Q96GM1
PSSYGNSSPPLNKMN	TP63	456	Q9H3D4
MSRPRNNPQTSSPQD	EBLN1	1	P0CF75
PMKHQSGQQRPPSIS	FAM126A	501	Q9BYI3
ASLNTPFIPANPNMS	EPHX2	356	P34913
QRSPNAIPMNKANSG	CRACD	51	Q6ZU35
SMALPQEQSQHPKPS	PYHIN1	411	Q6K0P9
PKTAMPSPGVSQNKQ	BCL9L	1011	Q86UU0
PPEPSLQMANTNFLS	CXXC4	16	Q9H2H0
MLPSPPKQKSSPVNN	CEP170P1	221	Q96L14
AVPQRTSPTGPKNMQ	MAPRE3	156	Q9UPY8
APASPMLGNASNPNK	MARK3	466	P27448
RKDSTSTPNNLPPSM	MARK4	491	Q96L34
TPPAMKNATSSKQLP	MAP7D1	51	Q3KQU3
PVPPSSPMNLQSNKL	KLF12	166	Q9Y4X4
LPQDISNKRTMTQPP	GPATCH2	171	Q9NW75
SRKIQTLQAPPDMAP	SDK2	1086	Q58EX2
SLPITNSFTKMQPPR	CARD11	541	Q9BXL7
PVNRENFTQTLPKMP	FAM171B	576	Q6P995
APLTKQSRSPSFNMQ	FAM126B	511	Q8IXS8
SARTMQSKPSAPPQD	PTPRD	601	P23468
QTFAVPNPIRKPASM	NR4A2	216	P43354
SNHPAMTKSDLQPPN	TOM1L1	426	O75674
RSSSNNSAPPKPMSL	TCP10L	156	Q8TDR4
MLSQNVPQKQSDSPP	PWWP3B	116	Q5H9M0
MSHPSPQAKPSNPSN	PPID	1	Q08752
KNALRNMPPRLPANT	KERA	201	O60938
LSSPGPKLDNSPNMN	NCOA3	541	Q9Y6Q9
PKLDNSPNMNITQPS	NCOA3	546	Q9Y6Q9
SPTMNPALNPTRAPK	SLITRK2	286	Q9H156
METSRSPSPQFAPQK	SHROOM2	1166	Q13796
TQRPKPIDQNFQPMS	SHROOM4	801	Q9ULL8
NGQKSRTNKMPPHPL	SHISA9	346	B4DS77
SMKVQISSQNPPPSP	TANC1	1551	Q9C0D5
LTAPTQAPMSNSPSK	POLH	501	Q9Y253
SQSPMFPPTHKRENS	SPATA31C1	951	P0DKV0
MLNVPSQSFPAPRSQ	CYB5R4	1	Q7L1T6
PTMASVPALQLTPAN	BRD2	46	P25440
PNIRNMAPNSLSAPT	TRAF3IP2	46	O43734
PNRSSPSIICMPKQQ	CNOT2	166	Q9NZN8
MPKQQPSRQPFTVNS	CNOT2	176	Q9NZN8
DSNQNMQSLLPAPPT	SS18L1	66	O75177
MGKPLNPISSNSPAH	NCOA2	391	Q15596
RSLTPSPMNIPGSNQ	TRAK1	416	Q9UPV9
PNSTNLPRNPSMADY	XIAP	251	P98170
MQSSSAKQKTPPPVA	SYNPO2	746	Q9UMS6
VNSALAMKQALPPRP	SYNPO2	996	Q9UMS6
AMKQALPPRPVNAAS	SYNPO2	1001	Q9UMS6
NVPPAISMPQKSFNA	NCAM2	206	O15394
QQASPPQLPKAMFSE	SEC16A	1066	O15027
DSNQNMQSLLPAPPT	SS18	66	Q15532
AQSSRPPSQPLQMLG	SRRM4	236	A7MD48
MDNLKSQSPLPEQSP	WDFY4	1681	Q6ZS81
TSTNFSPMRPQQPNL	PHF3	1791	Q92576
SPMRPQQPNLQHLKS	PHF3	1796	Q92576
MRNALGNQSTPAPPT	TACC2	1671	O95359
NLQSPLKMTNSPVLP	ZEB1	676	P37275
MSKQQPTQFINPETP	SEPTIN2	1	Q15019
ISARTDLAQMPKPQP	TRIM64C	251	A6NLI5
PSPLSSSYKPMLNNN	TTLL4	206	Q14679
ATSRLPPNLSNPNMD	TET2	1736	Q6N021
ASAQPIQKPRMSLPE	ZNF438	101	Q7Z4V0
KNNSPMAANQTPTLR	TRRAP	2376	Q9Y4A5
RSPPKLKNSSMDAPN	HIVEP1	231	P15822
QSMKLPPSNSALPNQ	TNRC6A	1296	Q8NDV7
KPNPQAMAALFLSAP	ZNF34	16	Q8IZ26
LPSLQQNLPMPAQRS	N4BP1	836	O75113
NMNPKLDLPNRPETS	MYOF	1991	Q9NZM1
AFQTPKSSQMPRPSV	NDC1	411	Q9BTX1